



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12Q 1/68	A1	(11) International Publication Number: WO 00/06776 (43) International Publication Date: 10 February 2000 (10.02.2000)
(21) International Application Number: PCT/US99/16675 (22) International Filing Date: 22 July 1999 (22.07.1999) (30) Priority Data: 60/094,391 28 July 1998 (28.07.1998) US (60) Parent Application or Grant AXYS PHARMACEUTICALS, INC. [/]; (). GALVIN, Margaret [/]; (). MILLER, Andrew [/]; (). PENNY, Laura [/]; (). RIEDY, Michael [/]; (). GALVIN, Margaret [/]; (). MILLER, Andrew [/]; (). PENNY, Laura [/]; (). RIEDY, Michael [/]; (). SHERWOOD, Pamela, J. ; ().		Published
(54) Title: GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7 (UGT2B7) AND 2B15 (UGT2B15) GENES (54) Titre: ETABLISSEMENT DU GENOTYPE DE GENES HUMAINS DE L'UDP-GLUCORONOSYL-TRANSFERASE 2B4 (UGT2B4), 2B7 (UGT2B7) ET 2B15 (UGT2B15) (57) Abstract <p>Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.</p> (57) Abrégé <p>Des polymorphismes génétiques ont été identifiés dans les gènes humains de UGT2B4, UGT2B7 et UGT2B15, qui modifient l'activité de UGT2B. Selon l'invention on utilise des acides nucléiques comprenant les séquences polymorphiques pour cribler des patients, à la recherche du métabolisme modifié de substrats UGT2B, d'interactions potentielles médicamenteuses et d'effets secondaires, de même qu'à la recherche de maladies induites par une exposition ambiante ou professionnelle aux toxines. On utilise les acides nucléiques pour établir des modèles animaux, cellulaires et in vitro, du métabolisme des médicaments.</p>		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/68	A1	(11) International Publication Number: WO 00/06776 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/16675 (22) International Filing Date: 22 July 1999 (22.07.99) (30) Priority Data: 60/094,391 28 July 1998 (28.07.98) US (71) Applicant (for all designated States except US): AXYS PHARMACEUTICALS, INC. [US/US]; 180 Kimball Way, South San Francisco, CA 94080 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GALVIN, Margaret [US/US]; 7768 Corte Promenade, Carlsbad, CA 92009 (US). MILLER, Andrew [US/US]; 2131 Old Stone Mill Drive, Cranbury, NJ 08512 (US). PENNY, Laura [US/US]; 3903 Falcon Street, San Diego, CA 92103 (US). RIEDY, Michael [US/US]; 4066 Gresham Street #B, San Diego, CA 92109 (US). (74) Agent: SHERWOOD, Pamela, J.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7 (UGT2B7) AND 2B15 (UGT2B15) GENES (57) Abstract Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and <i>in vitro</i> models for drug metabolism.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

5

10

15

20

25

30

35

40

45

50

55

**GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7
(UGT2B7) and 2B15 (UGT2B15) GENES**

INTRODUCTION

The metabolic processes commonly involved in the biotransformation of xenobiotics have been classified into functionalization reactions (phase I reactions), in which lipophilic compounds are modified via monooxygenation, dealkylation, reduction, aromatization, or hydrolysis. These modified molecules can then be substrates for the phase II reactions, often called conjugation reactions, as they conjugate a functional group with a polar, endogenous compound. Drug glucuronidation, a major phase II conjugation reaction in the mammalian detoxification system, is catalyzed by the UDP-glucuronosyltransferases (UGTs) (Batt AM, et al. (1994) Clin Chim Acta 226:171-190; Burchell et al. (1995) Life Sci. 57:1819-31).

The UGTs are a family of enzymes that catalyze the glucuronic acid conjugation of a wide range of endogenous and exogenous substrates including phenols, alcohols, amines and fatty acids. The reactions catalyzed by UGTs permit the conversion of a large range of toxic endogenous/xenobiotic compounds to more water-soluble forms for subsequent excretion (Parkinson A (1996) Toxicol Pathol 24:48-57).

The UGT isoenzymes are located primarily in hepatic endoplasmic reticulum and nuclear envelope (Parkinson A (1996) Toxicol Pathol 24:48-57), though they are also expressed in other tissues such as kidney and skin. UGTs are encoded by a large multigene superfamily that has evolved to produce catalysts with differing but overlapping substrate specificities. Three families, UGT1, UGT2, and UGT8, have been identified within the superfamily. UGTs are assigned to one the subfamilies based on amino acid sequence identity, e.g., UGT1 family members have greater than 45% amino acid sequence identity (Mackenzie et al. (1997) Pharmacogenetics 7:255-69).

A single gene encodes several human UGT1 isoforms, the substrate specificity of each of which is thought to arise from differential splicing of a number of substrate-specific 5-prime regions of a single mRNA transcript to a shared 3-prime portion. On the other hand, members of the mammalian UGT2 gene subfamily, which encode the odorant and steroid-metabolizing isoforms, show nucleotide differences in sequence throughout the length of the cDNAs. This suggested that the UGT2 isoenzymes are encoded by several independent genes. The UGT2 genes have been further divided on the basis of their tissue-specific expression patterns into the UGT2A gene subfamily, which encodes

5 olfactory-specific isoforms, and the UGT2B gene subfamily, which encodes
steroid-metabolizing isoforms in the liver. Monaghan *et al.* (1994) Genomics 23:498-499
mapped the UGT2B9 and the UGT2B15 genes to chromosome 4q13, giving a provisional
ordering of the genes as UGT2B9-UGT2B4-UGT2B15. The UGT2B subfamily contains
10 5 phenobarbital-inducible genes, as well as numerous genes that are constitutively expressed
and are involved in the glucuronidation of endogenous steroids and biogenic amines
(Mackenzie, *et al. supra.*) Evidence suggests that UGT2B4 is exclusively expressed in
human liver, and not in human kidney. Levesque *et al.* (1997) Pharmacogenetics 7:317; and
15 Coffman *et al.* (1997) Drug Metabol. and Dispos. 25:1-4, describe UGT2B gene
polymorphisms.

Alteration of the expression or function of UGTs may affect drug metabolism. For
example, there may be common polymorphisms in the human UGT2B gene that alter
20 expression or function of the protein product and cause drug exposure-related phenotypes.

Thus, there is a need in the field to identify UGT2B polymorphisms in order to provide a
15 better understanding of drug metabolism and the diagnosis of drug exposure-related
phenotypes.

SUMMARY OF THE INVENTION

Genetic sequence polymorphisms are identified in the UGT2B4, UGT2B7 and
20 30 UGT2B15 genes, herein generically referred to as "UGT2B genes". Nucleic acids
comprising the polymorphic sequences are used in screening assays, and for genotyping
individuals. The genotyping information is used to predict an individuals' rate of metabolism
for UGT2B substrates, potential drug-drug interactions, and adverse/side effects. Specific
35 polynucleotides include the polymorphic UGT2B4 sequences set forth in SEQ ID NOs:25-38;
25 the polymorphic UGT2B7 sequences set forth in SEQ ID NOs:84-111; and the polymorphic
UGT2B15 sequences set forth in SEQ ID NOs:147-164.

The nucleic acid sequences of the invention may be provided as probes for detection
40 of UGT2B locus polymorphisms, where the probe comprises a polymorphic sequence of
SEQ ID NOs:25-38; 84-111 and 147-164. The sequences may further be utilized as an
30 array of oligonucleotides comprising two or more probes for detection of UGT2B locus
polymorphisms.

Another aspect of the invention provides a method for detecting in an individual a
polymorphism in UGT2B metabolism of a substrate, where the method comprises analyzing
the genome of the individual for the presence of at least one UGT2B polymorphism; wherein

the presence of the predisposing polymorphism is indicative of an alteration in UGT2B expression or activity. The analyzing step of the method may be accomplished by detection of specific binding between the individual's genomic DNA with an array of oligonucleotides comprising UGT2B locus polymorphic sequences. In other embodiments, the alteration in UGT2B expression or activity is tissue specific, or is in response to a UGT2B modifier that induces or inhibits UGT2B expression.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

UGT2B Reference Sequences. SEQ ID NOs: 1-6 list the sequence of the reference UGT2B4 exons, where exon 1 is SEQ ID NO:1, exon 2 is SEQ ID NO:2 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST. The cDNA sequence is set forth in SEQ ID NO:7, and the encoded amino acid sequence in SEQ ID NO:8.

SEQ ID NO:39 lists the sequence of the UGT2B7 cDNA sequence, the encoded polypeptide is provided in SEQ ID NO:40. SEQ ID NOs: 41-45 list the sequence of the reference UGT2B7 exons, where exon 1 is SEQ ID NO:41, exon 2 is SEQ ID NO:42 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST.

SEQ ID NO:112 lists the sequence of the UGT2B15 cDNA sequence, the encoded polypeptide is provided in SEQ ID NO:113. SEQ ID NOs:114-118 list the sequence of the reference UGT2B15 exons, where exon 1 is SEQ ID NO:114, exon 2 is SEQ ID NO:115 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST.

Primers. The PCR primers for amplification of polymorphic sequences are set forth as SEQ ID NOs:9-14; 46-66; and 135-146. The primers used in sequencing isolated polymorphic sequences are presented as SEQ ID NOs:15-24; 67-83; and 119-134.

Polymorphisms. Polymorphic sequences of UGT2B4 are presented as SEQ ID NOs:25-38. Polymorphic sequences of UGT2B7 are presented as SEQ ID NOs:84-111. Polymorphic sequences of UGT2B15 are presented as SEQ ID NO:147-164.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Pharmacogenetics is the association between an individual's genotype and that individual's ability to metabolize or react to a therapeutic agent. Differences in metabolism or target sensitivity can lead to severe toxicity or therapeutic failure by altering the relation between bioactive dose and blood concentration of the drug. Relationships between polymorphisms in metabolic enzymes or drug targets and both response and toxicity can be used to optimize therapeutic dose administration.

Genetic polymorphisms are identified in the UGT2B4, UGT2B7 and UGT2B15 genes. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell culture and *in vitro* cell-free models for drug metabolism.

Definitions

It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a construct" includes a plurality of such constructs and reference to "the UGT2B nucleic acid" includes reference to one or more nucleic acids and equivalents thereof known to those skilled in the art, and so forth. All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs unless clearly indicated otherwise.

UGT2B4 reference sequence. The sequence of human UGT2B4 cDNA may be accessed through Genbank, accession number Y00317, and is provided in SEQ ID NOs:1-7.

The amino acid sequence of UGT2B4 is listed as SEQ ID NO:8. The sequence of human UGT2B7 may be accessed through Genbank, accession number 600068, and in the SEQLIST as described above. The sequence of human UGT2B15 may be accessed through Genbak, accession number 600069, and in the SEQLIST as described above. The

5 nucleotide sequences provided herein differ from the published sequence at certain positions throughout the sequence. Where there is a discrepancy the provided sequence is used as a reference.

10 The term "wild-type" may be used to refer to the reference coding sequences of 5 UGT2B4, UGT2B7 and UGT2B15, and the term "variant", or "UGT2B" to refer to the provided variations in the UGT2B sequences. The UGT2B4, UGT2B7 and UGT2B15 sequences are generically referred to as "UGT2B", and may be further distinguished by the species, e.g. human, mouse, etc., or by the specific gene number, e.g. UGT2B4, UGT2B7, 15 etc. Where there is no published form, such as in the intron sequences, the term wild-type 10 may be used to refer to the most commonly found allele. It will be understood by one of skill in the art that the designation as "wild-type" is merely a convenient label for a common allele, and should not be construed as conferring any particular property on that form of the 20 sequence.

15 *UGT2B polymorphic sequences.* It has been found that specific sites in the UGT2B4, UGT2B7 and UGT2B15 genes sequence are polymorphic, i.e. within a population, 25 more than one nucleotide (G, A, T, C) is found at a specific position. Polymorphisms may provide functional differences in the genetic sequence, through changes in the encoded polypeptide, changes in mRNA stability, binding of transcriptional and translation factors to 30 the DNA or RNA, and the like. The polymorphisms are also used as single nucleotide polymorphisms (SNPs) to detect genetic linkage to phenotypic variation in activity and expression of the particular UGT2B protein.

35 SNPs are generally biallelic systems, that is, there are two alleles that an individual may have for any particular marker. SNPs, found approximately every kilobase, offer the 25 potential for generating very high density genetic maps, which will be extremely useful for developing haplotyping systems for genes or regions of interest, and because of the nature of SNPs, they may in fact be the polymorphisms associated with the disease phenotypes 40 under study. The low mutation rate of SNPs also makes them excellent markers for studying complex genetic traits.

30 SNPs are provided in the UGT2B4, UGT2B7 and UGT2B15 intron and exon 45 sequences. Tables 4, 7 and 10, and the corresponding sequence listing, provide both forms of each polymorphic sequence. For example, SEQ ID NO:37 and 38 are the alternative forms of a single polymorphic site. The provided sequences also encompass the complementary sequence corresponding to any of the provided polymorphisms.

5 In order to provide an unambiguous identification of the specific site of a polymorphism, sequences flanking the polymorphic site are shown in the tables, where the 5' and 3' flanking sequence is non-polymorphic, and the central position, shown in bold, is variable. It will be understood that there is no special significance to the length of non-polymorphic flanking sequence that is included, except to aid in positioning the polymorphism in the genomic sequence. The UGT2B exon sequences have been published, and therefore one of each pair of the sequences from exons in Tables 4, 7 and 10 are publically known sequence. The intron sequence has not been published, and hence both forms of this polymorphic sequence is novel.

10 As used herein, the term "UGT2B4, UGT2B7 and UGT2B15 genes" is intended to generically refer to both the wild-type and variant forms of the sequence, unless specifically denoted otherwise. As it is commonly used in the art, the term "gene" is intended to refer to the genomic region encompassing the 5' UTR, exons, introns, and the 3' UTR. Individual segments may be specifically referred to, *e.g.* exon 2, intron 5, *etc.* Combinations of such segments that provide for a complete UGT2B protein may be referred to generically as a protein coding sequence.

15 Nucleic acids of interest comprise the provided UGT2B^v nucleic acid sequence(s), as set forth in Tables 4, 7 and 10. Such nucleic acids include short hybridization probes, protein coding sequences, variant forms of UGT2B cDNA, segments, *e.g.* exons, introns, *etc.*, and the like. Methods of producing nucleic acids are well-known in the art, including chemical synthesis, cDNA or genomic cloning, PCR amplification, *etc.*

20 For the most part, DNA fragments will be of at least 15 nt, usually at least 20 nt, often at least 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening, *etc.* Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide, promoter motifs, *etc.* For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art.

25 The UGT2B nucleic acid sequences are isolated and obtained in substantial purity, generally as other than an intact or naturally occurring mammalian chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a UGT2B sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

For screening purposes, hybridization probes of the polymorphic sequences may be used where both forms are present, either in separate reactions, spatially separated on a solid phase matrix, or labeled such that they can be distinguished from each other. Assays may utilize nucleic acids that hybridize to one or more of the described polymorphisms.

An array may include all or a subset of the polymorphisms listed in Tables 4, 7 and 10. One or both polymorphic forms may be present in the array, for example the polymorphism of SEQ ID NO:37 and 38 may be represented by either, or both, of the listed sequences. Usually such an array will include at least 2 different polymorphic sequences, *i.e.* polymorphisms located at unique positions within the locus, and may include all of the provided polymorphisms. Arrays of interest may further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for pharmacogenetic screening, *e.g.* UGT1, other UGT2 sequences, cytochrome oxidase polymorphisms, *etc.* The oligonucleotide sequence on the array will usually be at least about 12 nt in length, may be the length of the provided polymorphic sequences, or may extend into the flanking regions to generate fragments of 100 to 200 nt in length. For examples of arrays, see Ramsay (1998) Nat. Biotech. 16:40-44; Hacia *et al.* (1996) Nature Genetics 14:441-447; Lockhart *et al.* (1996) Nature Biotechnol. 14:1675-1680; and De Risi *et al.* (1996) Nature Genetics 14:457-460.

Nucleic acids may be naturally occurring, *e.g.* DNA or RNA, or may be synthetic analogs, as known in the art. Such analogs may be preferred for use as probes because of superior stability under assay conditions. Modifications in the native structure, including alterations in the backbone, sugars or heterocyclic bases, have been shown to increase intracellular stability and binding affinity. Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoramidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoramidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage.

Sugar modifications are also used to enhance stability and affinity. The α -anomer of deoxyribose may be used, where the base is inverted with respect to the natural β -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without compromising affinity.

Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and

5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

UGT2B polypeptides. A subset of the provided nucleic acid polymorphisms in UGT2B exons confer a change in the corresponding amino acid sequence. Using the amino acid sequence provided in SEQ ID NO:8 as a reference for UGT2B4, the amino acid polymorphisms of the invention include lys→asn, pos. 40; and glu→asp, pos. 454. Using the amino acid sequence provided in SEQ ID NO:40 as a reference for UGT2B7, the amino acid polymorphisms of the invention include leu→phe, pos. 107; thr→ile, pos. 179; and lys→gln, pos. 430. Using the amino acid sequence provided in SEQ ID NO:125 as a reference for UGT2B15, the amino acid polymorphisms of the invention include ser→gly, pos. 15; asp→tyr, pos. 85; leu→pro, pos. 170; his→gln, pos. 282; ala→val, pos. 398; val→ile, pos. 443; and thr→lys, pos. 523.

Polypeptides comprising at least one of the provided polymorphisms (UGT2B^y polypeptides) are of interest. The term "UGT2B^y polypeptides" as used herein includes complete UGT2B protein forms, e.g. such splicing variants as known in the art, and fragments thereof, which fragments may comprise short polypeptides, epitopes, functional domains; binding sites; etc.; and including fusions of the subject polypeptides to other proteins or parts thereof. Polypeptides will usually be at least about 8 amino acids in length, more usually at least about 12 amino acids in length, and may be 20 amino acids or longer, up to substantially the complete protein.

The UGT2B4, UGT2B7 and UGT2B15 genetic sequences, including polymorphisms, may be employed for polypeptide synthesis. For expression, an expression cassette may be employed, providing for a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. Various transcriptional initiation regions may be employed that are functional in the expression host. The polypeptides may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. Small peptides can also prepared by chemical synthesis.

5 **Substrate.** A substrate is a chemical entity that is modified by UGT2B4, UGT2B7 or
UGT2B15, usually under normal physiological conditions. Although the duration of drug
action tends to be shortened by metabolic transformation, drug metabolism is not
"detoxification". Frequently the metabolic product has greater biologic activity than the drug
10 5 itself. In some cases the desirable pharmacologic actions are entirely attributable to
metabolites, the administered drugs themselves being inert. Likewise, the toxic side effects
of some drugs may be due in whole or in part to metabolic products.

15 Substrates can be either endogenous substrates, *i.e.* substrates normally found
within the natural environment of UGT2B, such as estriol, or exogenous, *i.e.* substrates that
10 10 are not normally found within the natural environment of UGT2B. UGT2B catalyzes
glucuronidation of its substrates. The enzymes are specific for UDP-glucuronic acid, and not
other UDP sugars.

20 Exemplary UGT2B4 substrates (*i.e.*, substrates of wild-type UGT2B4 and/or
UGT2B4* polypeptides) include, but are not necessarily limited to estriol and the catechol
15 15 estrogens 4-hydroxyestrone, and 2-hydroxyestriol, 2-aminophenol, 4-methylumbelliferone,
1-naphthol, 4-hydroxybiphenyl and 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl,
25 25 menthol, *etc.*, among other substrates (Burchell *et al.* (1991) DNA Cell Biol 10:487-494, Jin
CJ, *et al.* (1993) Biochem Biophys Res Commun 194:498-503).

30 Exemplary UGT2B7 substrates (*i.e.*, substrates of wild-type UGT2B7 and/or
UGT2B7* polypeptides) include, but are not necessarily limited to oxazepam, hyodeoxycholic
30 20 acid, estriol, S-naproxen, ketoprofen, ibuprofen, fenoprofen, clofibric acid (Patel *et al.* (1995)
Pharmacogenetics 5(1):43-49), morphine (Coffman *et al.* (1997) Drug Metabolism and
Disposition 25:1-4), DMXAA (5,6-dimethylxantheonone-4-acetic acid) (Miners *et al.* (1997)
35 35 Cancer Res 57:284), 2-Hydroxy AAF, 4 methylumbelliferone, carboxylic acid drugs (BP-7,8-
trans diol) (Burchell *et al.*, *supra.*)

40 Exemplary UGT2B15 substrates (*i.e.*, substrates of wild-type UGT2B15 and/or
UGT2B15* polypeptides) include, but are not necessarily limited to 4-hydroxybiphenyl, 1-
40 40 naphthol, 4 methylumbelliferone, naringenin, eugenol (Burchell *et al.*, *supra.*), simple
phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones; endogenous
30 30 estrogens and androgens (Green *et al.* (1994) Drug Metabolism and Disposition 22:799.

45 **Modifier.** A modifier is a chemical agent that modulates the action of a UGT2B
molecule, either through altering its enzymatic activity (enzymatic modifier) or through

modulation of expression (expression modifier, e.g., by affecting transcription or translation).
In some cases the modifier may also be a substrate.

Pharmacokinetic parameters. Pharmacokinetic parameters provide fundamental data for designing safe and effective dosage regimens. A drug's volume of distribution, clearance, and the derived parameter, half-life, are particularly important, as they determine the degree of fluctuation between a maximum and minimum plasma concentration during a dosage interval, the magnitude of steady state concentration and the time to reach steady state plasma concentration upon chronic dosing. Parameters derived from *in vivo* drug administration are useful in determining the clinical effect of a particular UGT2B genotype.

Expression assay. An assay to determine the effect of a sequence polymorphism on UGT2B expression. Expression assays may be performed in cell-free extracts, or by transforming cells with a suitable vector. Alterations in expression may occur in the basal level that is expressed in one or more cell types, or in the effect that an expression modifier has on the ability of the gene to be inhibited or induced. Expression levels of a variant alleles are compared by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β -galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like.

Gel shift or electrophoretic mobility shift assay provides a simple and rapid method for detecting DNA-binding proteins (Ausubel, F.M. *et al.* (1989) In: Current Protocols in Molecular Biology, Vol. 2, John Wiley and Sons, New York). This method has been used widely in the study of sequence-specific DNA-binding proteins, such as transcription factors. The assay is based on the observation that complexes of protein and DNA migrate through a nondenaturing polyacrylamide gel more slowly than free DNA fragments or double-stranded oligonucleotides. The gel shift assay is performed by incubating a purified protein, or a complex mixture of proteins (such as nuclear or cell extract preparations), with an end-labeled DNA fragment containing the putative protein binding site. The reaction products are then analyzed on a nondenaturing polyacrylamide gel. The specificity of the DNA-binding protein for the putative binding site is established by competition experiments using DNA fragments or oligonucleotides containing a binding site for the protein of interest, or other unrelated DNA sequences.

5 Expression assays can be used to detect differences in expression of polymorphisms with respect to tissue specificity, expression level, or expression in response to exposure to various substrates, and/or timing of expression during development. For example, since UGT2B4 is expressed in liver, polymorphisms could be evaluated for expression in tissues
10 5 other than liver, or expression in liver tissue relative to a reference UGT2B4 polypeptide.

Substrate screening assay. Substrate screening assays are used to determine the metabolic activity of a UGT2B protein or peptide fragment on a substrate. Many suitable assays are known in the art, including the use of primary or cultured cells, genetically
15 10 modified cells (e.g., where DNA encoding the UGT2B polymorphism to be studied is introduced into the cell within an artificial construct), cell-free systems, e.g. microsomal preparations or recombinantly produced enzymes in a suitable buffer, or in animals, including human clinical trials (see, e.g., Burchell et al. (1995) *Life Sci.* 57:1819-1831, specifically incorporated herein by reference. Where genetically modified cells are used, since most cell
20 15 lines do not express UGT2B activity (liver cells lines being the exception), introduction of artificial construct for expression of the UGT2B polymorphism into many human and non-human cell lines does not require additional modification of the host to inactivate endogenous UGT2B expression/activity. Clinical trials may monitor serum, urine, etc. levels of the substrate or its metabolite(s).

20 Typically a candidate substrate is input into the assay system, and the conversion to a metabolite is measured over time. The choice of detection system is determined by the substrate and the specific assay parameters. Assays are conventionally run, and will include negative and positive controls, varying concentrations of substrate and enzyme, etc.

35 25 *Genotyping:* UGT2B genotyping is performed by DNA or RNA sequence and/or hybridization analysis of any convenient sample from a patient, e.g. biopsy material, blood sample (serum, plasma, etc.), buccal cell sample, etc. A nucleic acid sample from an individual is analyzed for the presence of polymorphisms in UGT2B, particularly those that affect the activity or expression of UGT2B. Specific sequences of interest include any
40 30 polymorphism that leads to changes in basal expression in one or more tissues, to changes in the modulation of UGT2B expression by modifiers, or alterations in UGT2B substrate specificity and/or activity.

5 *Linkage Analysis:* Diagnostic screening may be performed for polymorphisms that
are genetically linked to a phenotypic variant in UGT2B activity or expression, particularly
through the use of microsatellite markers or SNPs. The microsatellite marker or SNP itself
may not phenotypically expressed, but is linked to sequences that result in altered activity
10 5 or expression. Two polymorphic variants may be in linkage disequilibrium, *i.e.* where alleles
show non-random associations between genes even though individual loci are in Hardy-
Weinberg equilibrium.

15 Linkage analysis may be performed alone, or in combination with direct detection of
phenotypically evident polymorphisms. The use of microsatellite markers for genotyping is
well documented. For examples, see Mansfield *et al.* (1994) *Genomics* 24:225-233; and
10 10 Ziegler *et al.* (1992) *Genomics* 14:1026-1031. The use of SNPs for genotyping is illustrated
in Underhill *et al.* (1996) *Proc Natl Acad Sci U S A* 93:196-200.

20 *Transgenic animals.* The subject nucleic acids can be used to generate genetically
15 15 modified non-human animals or site specific gene modifications in cell lines. The term
"transgenic" is intended to encompass genetically modified animals having a deletion or
25 25 other knock-out of UGT2B4, UGT2B7 or UGT2B15 activity, having an exogenous UGT2B4,
UGT2B7 or UGT2B15 gene that is stably transmitted in the host cells, or having an
exogenous UGT2B promoter operably linked to a reporter gene. Transgenic animals may
30 20 be made through homologous recombination, where the UGT2B locus is altered.
Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for
stable integration include plasmids, retroviruses and other animal viruses, YACs, and the
like. Of interest are transgenic mammals, *e.g.* cows, pigs, goats, horses, *etc.*, and
35 35 particularly rodents, *e.g.* rats, mice, *etc.*

25 *Genetically Modified Cells.* Primary or cloned cells and cell lines are modified by the
introduction of vectors comprising UGT2B4, UGT2B7 and UGT2B15 genetic polymorphisms.
40 40 The gene may comprise one or more variant sequences, preferably a haplotype of
commonly occurring combinations. In one embodiment of the invention, a panel of two or
30 30 more genetically modified cell lines, each cell line comprising a UGT2B polymorphism, are
provided for substrate and/or expression assays. The panel may further comprise cells
45 45 genetically modified with other genetic sequences, including polymorphisms, particularly
other sequences of interest for pharmacogenetic screening, *e.g.* UGT1, other UGT2
sequences, cytochrome oxidase polymorphisms, *etc.*

5 Vectors useful for introduction of the gene include plasmids and viral vectors, e.g. retroviral-based vectors, adenovirus vectors, etc. that are maintained transiently or stably in mammalian cells. A wide variety of vectors can be employed for transfection and/or integration of the gene into the genome of the cells. Alternatively, micro-injection may be employed, fusion, or the like for introduction of genes into a suitable host cell.

Genotyping Methods

15 The effect of a polymorphism in the UGT2B4, UGT2B7 or UGT2B15 gene sequence on the response to a particular substrate or modifier is determined by *in vitro* or *in vivo* assays. Such assays may include monitoring the metabolism of a substrate during clinical trials to determine the UGT2B enzymatic activity, specificity or expression level. Generally, *in vitro* assays are useful in determining the direct effect of a particular polymorphism, while clinical studies will also detect an enzyme phenotype that is genetically linked to a polymorphism.

20 The response of an individual to the substrate or modifier can then be predicted by determining the UGT2B genotype, with respect to the polymorphism. Where there is a differential distribution of a polymorphism by racial background, guidelines for drug administration can be generally tailored to a particular ethnic group.

25 The basal expression level in different tissue may be determined by analysis of tissue samples from individuals typed for the presence or absence of a specific polymorphism. Any convenient method may be used, e.g. ELISA, RIA, etc. for protein quantitation, northern blot or other hybridization analysis, quantitative RT-PCR, etc. for mRNA quantitation. The tissue specific expression is correlated with the genotype.

30 The alteration of UGT2B expression in response to a modifier is determined by administering or combining the candidate modifier with an expression system, e.g. animal, cell, *in vitro* transcription assay, etc. The effect of the modifier on UGT2B transcription and/or steady state mRNA levels is determined. As with the basal expression levels, tissue specific interactions are of interest. Correlations are made between the ability of an expression modifier to affect UGT2B activity, and the presence of the provided polymorphisms. A panel of different modifiers, cell types, etc. may be screened in order to determine the effect under a number of different conditions.

35 A UGT2B polymorphism that results in altered enzyme activity or specificity is determined by a variety of assays known in the art. The enzyme may be tested for metabolism of a substrate *in vitro*, for example in defined buffer, or in cell or subcellular

lysates, where the ability of a substrate to be metabolized by UGT2B4, UGT2B7 or UGT2B15 under physiologic conditions is determined. Where there are not significant issues of toxicity from the substrate or metabolite(s), *in vivo* human trials may be utilized, as previously described.

The genotype of an individual is determined with respect to the provided UGT2B4, UGT2B7 and UGT2B15 polymorphisms. The genotype is useful for determining the presence of a phenotypically evident polymorphism, and for determining the linkage of a polymorphism to phenotypic change.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki *et al.* (1985) Science 230:1350-1354, and a review of current techniques may be found in Sambrook *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2-14.33. Amplification may be used to determine whether a polymorphism is present, by using a primer that is specific for the polymorphism. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990) Nucleic Acids Res 18:2887-2890; and Delahunty *et al.* (1996) Am J Hum Genet 58:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. ³²P, ³⁵S, ³H; etc. The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, e.g. amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or

5 other methods. Hybridization with the variant sequence may also be used to determine its
presence, by Southern blots, dot blots, etc. The hybridization pattern of a control and variant
sequence to an array of oligonucleotide probes immobilized on a solid support, as described
10 in U.S. 5,445,934, or in WO95/35505, may also be used as a means of detecting the
presence of variant sequences. Single strand conformational polymorphism (SSCP)
analysis, denaturing gradient gel electrophoresis (DGGE), mismatch cleavage detection, and
heteroduplex analysis in gel matrices are used to detect conformational changes created by
15 DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a
polymorphism creates or destroys a recognition site for a restriction endonuclease
(restriction fragment length polymorphism, RFLP), the sample is digested with that
endonuclease, and the products size fractionated to determine whether the fragment was
20 digested. Fractionation is performed by gel or capillary electrophoresis, particularly
acrylamide or agarose gels.

In one embodiment of the invention, an array of oligonucleotides are provided, where
15 discrete positions on the array are complementary to one or more of the provided
polymorphic sequences, e.g. oligonucleotides of at least 12 nt, frequently 20 nt, or larger,
and including the sequence flanking the polymorphic position. Such an array may comprise
a series of oligonucleotides, each of which can specifically hybridize to a different
25 polymorphism. For examples of arrays, see Hacia *et al.* (1996) Nat Genet 14:441-447 and
DeRisi *et al.* (1996) Nat Genet 14:457-460.

The genotype information is used to predict the response of the individual to a
particular UGT2B substrate or modifier. Where an expression modifier inhibits UGT2B
expression, then drugs that are a UGT2B substrate will be metabolized more slowly if the
35 modifier is co-administered. Where an expression modifier induces UGT2B expression, a
co-administered substrate will typically be metabolized more rapidly. Similarly, changes in
25 UGT2B activity will affect the metabolism of an administered drug. The pharmacokinetic
effect of the interaction will depend on the metabolite that is produced, e.g. a prodrug is
40 metabolized to an active form, a drug is metabolized to an inactive form, an environmental
compound is metabolized to a toxin, etc. Consideration is given to the route of
30 administration, drug-drug interactions, drug dosage, etc.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art
with a complete disclosure and description of how to make and use the subject invention,

and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

EXAMPLE 1 Genotyping UGT2B4

Materials and Methods

DNA Samples. Blood specimens from approximately 48 individuals were collected after obtaining informed consent. All samples were stripped of personal identifiers to maintain confidentiality. The only data associated with a given blood samples was gender and self-reported major racial group designations in the United States (Caucasian, Hispanic, African American). Genomic DNA was isolated from these samples using standard techniques. DNA was stored either as a concentrated solution, or in a dried form in microtiter plates.

PCR amplifications. The primers used to amplify exons in which polymorphisms were found are shown in Table 1, and were designed with NBI's Oligo version 5.1 program. Sequences for exons in which no polymorphisms were found are not shown.

Table 1. UGT2B4 PCR Primers.

Region	Primary PCR Amplification		
	Forward/ Reverse	SEQ ID NO	Sequence
UGT2B4Exon 1	F	9.	Taccttttagtgtctcttgc
	R	10.	Ttctggagttctctgtatga
UGT2B4Exon 4	F	11.	Catccctgttctctcatt
	R	12.	Cgggactggaaaataaatat
UGT2B4Exon 6	F	13.	Ggggttcaccgtgtta
	R	14.	Aagccaagcagcactaa

Twenty-five nanograms of gDNA were amplified in the primary amplifications using the Perkin Elmer GeneAmp PCR kit according to the manufacturer's instructions in 25 μ l reactions with AmpliTaq Gold DNA polymerase. Reactions contained 25 mM $MgCl_2$ and 0.2 μ M of each primer. Thermal cycling was performed using a GeneAmp PCR System 9600

PCR machine (Perkin Elmer), utilizing a touch-down PCR protocol. The protocol, unless indicated otherwise in Table 2, consisted of an initial incubation of 95°C for 10 min, followed by ten cycles of 95°C for 20 sec, 64°C (minus 1°C per cycle) for 20 sec, 72°C for 2 min, six cycles of 95°C for 20 sec, 54°C for 20 sec, 72°C for 2 min, and nineteen cycles of 95°C for 20 sec, 54°C for 20 sec, 72°C for 2 min (plus 15 sec per cycle), and one final extension step of 72°C for 10 min.

For the secondary PCR reactions, one microliter of each primary PCR reaction was re-amplified using the primary PCR primers. The thermal cycling profile that was used for the primary PCR for an exon was also used for the secondary PCR.

Table 2.
Cycling Profile Modifications

Exon	Primary PCR	Secondary PCR
1	Touch-Down PCR step: 8 cycles 64° C (minus 1° C per cycle), for 15 sec Total Number of cycles: 35	same as Primary PCR
4	Touch-Down PCR step: 10 cycles 64° C (minus 1° C per cycle), for 15 sec Total Number of cycles: 35	same as Primary PCR
6	Touch-Down PCR step: 7 cycles 64° C (minus 1° C per cycle), for 15 sec Total Number of cycles: 35	same as Primary PCR

DNA sequencing. PCR products from 48 individuals (approximately 1/3 African American, 1/3 Caucasian, 1/3 Hispanic) were prepared for sequencing by treating 8 µl of each PCR product with 0.15 µl of exonuclease I (1.5 U/reaction), 0.3 µl of Shrimp Alkaline Phosphatase (0.3U/reaction), q.s. to 10 µl with MilliQ water, and incubated at 37°C for 30 min, followed by 72°C for 15 min. Cycle sequencing was performed on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions, with the following changes: (1) 2 µl of dRhodamine terminator premix, instead of 8 µl, (2) 10% (v/v) Dimethylsulfoxide was added to each individual nucleotide. The oligonucleotide primers (unlabelled), at 3 picomoles per reaction, used for the sequencing reactions are listed in

Table 3. Sequencing reactions, with a final volume of 5 μ l, were subjected to 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min, followed by ethanol precipitation. After decanting the ethanol, samples were evaporated to dryness using a SpeedVac for roughly 15 min and were resuspended in 2 μ l of loading buffer (5:1 deionized formamide:50 mM EDTA pH 8.0), heated to 94°C for 2 min, and were electrophoresed through 5.25% polyacrylamide/6M urea gels in an ABI Prism 377 DNA Sequencer, according to the manufacturer's instructions for sequence determination. All sequences were determined from both the 5' and 3' (sense and antisense) direction.

Table 3. Sequencing Primers

P. No.	F/R	SEQ ID NO	Forward Primer
1	F	15.	Ccacatgctcagactgttaa
	R	16.	Caaaaataccccactaccc
2	F	17.	Ccctgttcttctcattgta
	R	18.	Ttcagtaagctgtttcatgat
3,4	F	19.	Cctggccaaattgactt
	R	20.	Caggaacccagtcacatc
5	F	21.	Ggggaaaagagattaattacg
	R	22.	Agccaagcagcactaatc
6,7	F	23.	Tccaattcacaggttacatg
	R	24.	Agccaagcagcactaatc

Table 4.
Summary of UGT2B4 polymorphisms.

Exon	Nt change	AA change	SEQ ID	Sequence
1	G 157 C	Lys 40 Asn	25.	Tggatgaataaagacaatcctggat
			26.	Tggatgaataaacaacatcctggat
Int.4	T 61 C		27.	Aagtgttaatagttatcatgaaacaag
			28.	Aagtgttaatagctatcatgaaacaag
6	T 1411 A	Glu 454 Asp	29.	Tgaagccccttgatcgagcagcttct
			30.	Tgaagccccttgaacgagcagcttct
6	C 1412 A		31.	Tgaagccccttgatcgagcagcttct
			32.	Tgaagccccttgatagagcagcttct
6	T 1849 C		33.	Gatataaagccatacgagggttatattg
			34.	Gatataaagccatcgagggttatattg
6	A 1919 C		35.	Caggttacatgaaaaaaatttacta
			36.	Caggttacatgaaaaacaatttacta
6	A 2072 G		37.	Tgttgaggaagctaataaataattaa
			38.	Tgttgaggaaactaataaataattaa

Nucleotide variants in exons are numbered from first base in Sequence 1. Amino Acid changes are numbered beginning with the first methionine in the protein sequence provided in Sequence 1. The nucleotide variant in Intron 4 is numbered from the beginning of intron 4, as provided in Sequence 2.4.

EXAMPLE 2

UGT2B7 Genotyping

Twenty-five nanograms of gDNA were amplified in the primary amplifications using the Perkin Elmer GeneAmp PCR kit according to the manufacturer's instructions in 25 μ l reactions with AmpliTaq Gold DNA polymerase. Reactions contained 25 mM $MgCl_2$ and 0.2 μ M of each primer. Thermal cycling was performed using a GeneAmp PCR System 9600 PCR machine (Perkin Elmer), utilizing a touch-down PCR protocol. The exons for UGT2B7 were amplified using the following cycling conditions: An initial incubation at 96°C for 10 min., followed by 16 cycles of 95°C for 20 sec., 52°C for 20 sec., 72°C for 2 min., and nineteen cycles of 95°C for 20 sec, 52°C for 20 sec, 72°C for 2 min (plus 15 sec per cycle), and one final extension step of 72°C for 10 min.

For the secondary PCR reactions, one microliter of each primary PCR reaction was re-amplified using the primary PCR primers. The thermal cycling profile that was used for the primary PCR for an exon was also used for the secondary PCR.

The amplification primers are provided in Table 5, the sequencing primers in Table 6, and the polymorphisms in Table 7.

Table 5 PCR Primers for UGT2B7 Amplification			
Region		SEQ ID NO	Primer Sequence
UGT2B7 Exon 1	Primary F	46.	Ctggctaattatcttgg
	Primary R	47.	Cccactaccctgactttat
	Secondary F	48.	Ggacataaccatgagaaatg
	Secondary R	49.	Agctctgctcaaagacac
UGT2B7 Exon 2	Primary F	50.	Tgtccgatgctactattgaa
	Primary R	51.	Tgtgctaacccttgtaa
	Secondary F	52.	Ttttttctatcctgtcag
	Secondary R	53.	Cttaccaccacattt
UGT2B7 Exon 4	Primary F	54.	Ccctgatctcattcctact
	Primary R	55.	Aactggctattcttagatgtatg
	Secondary F	56.	Cattcctactcttatacagttctc
	Secondary R	57.	Cccccgattcagactat
UGT2B7 Exon 5	Primary F	58.	Ccctgatctcattcctact
	Primary R	59.	Aactggctattcttagatgtatg
	Secondary F	60.	Tcctccgaagctgaaac
	Secondary R	61.	Tataaaaaggatgaaactcacac
UGT2B7 Exon 6	Primary F	62.	Caagccccaagttatgt
	Primary R	63.	Cagtaggatccgcgatataa
	Secondary F	64.	Tctgaggggtttgtctgta
	Secondary R	65.	Ccgcgatataagttcaacaa

DNA sequencing. PCR products from 48 individuals were prepared for sequencing by treating 8 μ L of each PCR product with 0.15 μ L of exonuclease I (1.5U/reaction), 0.3 μ L of Shrimp Alkaline Phosphatase (0.3U/reaction), q.s. to 10 μ L with MilliQ water, and incubated at 37°C for 30 min, followed by 72°C for 15 min. Cycle sequencing was performed

5 on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism
dRhodamine Terminator Cycle Sequencing Ready Reaction Kit or the ABI Prism Big Dye
Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions,
with the following changes: For the ABI Prism dRhodamine Terminator kit, (1) 2 μ L of
10 dRhodamine terminator premix, instead of 8 μ L, (2) 10% (v/v) Dimethylsulfoxide was added
to each individual nucleotide, (3) 5 μ L total volume instead of 20 μ L. For the ABI Prism Big
Dye Terminator kit (1) 0.8 μ L of Big Dye terminator premix, instead of 8 μ L, and (2) 15 μ L
15 total volume instead of 20 μ L. The oligonucleotide primers (unlabeled), at 3 picomoles per
reaction, used for the sequencing reactions are listed in Table 6. Sequencing reactions, with
10 a final volume of 5 μ L, were subjected to 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and
60°C for 4 min, followed by ethanol precipitation. After decanting the ethanol, samples were
evaporated to dryness using a SpeedVac for roughly 15 min and were resuspended in 2 μ L
20 of loading buffer (5:1 deionized formamide:50 mM EDTA pH 8.0), heated to 94°C for 2 min,
and were electrophoresed through 5.25% polyacrylamide/6M urea gels in an ABI Prism 377
15 DNA Sequencer, according to the manufacturer's instructions for sequence determination.
All sequences were determined from both the 5' and 3' (sense and antisense) direction.

Table 6
Sequencing Primers UGT2B7

P. No.	F/R	SEQ ID NO	Primer Sequence
1, 2	F	66.	Ggacataacctgagaaatg
	R	67.	Ttaagagcggatgagttgt
3, 4	F	68.	Tcatcatgcaacagattaag
	R	69.	Cactacagggaaaaatagca
5	F	70.	Acccttgggtacagtctca
	R	71.	Agctctgcttcaaagacac
6, 7	F	72.	Ttgcctacattattctaacc
	R	73.	Ctttaccacccattt
8, 9	F	74.	Cattcctactctttatacagttctc
	R	75.	Ccccgattcagactat
10	F	76.	Cattcctactctttatacagttctc
	R	77.	Ccccgattcagactat
11, 12	F	78.	Tcctccgaagtcgaaac
	R	79.	Tataaaaaggatgaaactcacac
13	F	80.	Tctgaggggtttgtctgta
	R	81.	Tttttgtctcaggaagaaaga
14	F	82.	Aaaaaaagaaaaaaatctttc
	R	83.	Ccgcatataagttcaacaa

Table 7

Summary of Sequence Polymorphisms UGT2B7

N	Exon	Nt change	AA change	SEQ ID NO.	Sequence
1	1	G 13 A		84.	Tgcattgcaccaggatgtctgt
				85.	Tgcattgcaccaagatgtctgt
2	1	T 151 C	Leu 107 Phe	86.	Tcctggatgagcttattcagaga
				87.	Tcctggatgagcctattcagaga
3	1	A 236 T		88.	Catttgggtataattttcac
				89.	Catttgggtttattttcac
4	1	A 286 G		90.	Cataactagaaagtctgtaa
				91.	Cataactaggaagtctgtaa
5	1	C 450 T	Thr 179 Ile	92.	Cctggctacacttttgaaaa
				93.	Cctggctacatttttgaaaa
6	2	A 14 G		94.	Gaagaccactacattatctg
				95.	Gaagaccactacgttatctg
7	2	AT 80-81 TC		96.	Aattttcagttccatccactctt
				97.	Aattttcagttcctcatccactctt
8	4	C 57 G		98.	Taggtctcaatactcggctcta
				99.	Taggtctcaatactcggctgta
9	4	C 60 T		100.	Tacaagtggataccccaga
				101.	Tataagtggataccccaga
10	In.4	A 154 del		102.	Gggagaaagaatacattataattttt
				103.	Gggagaaagaataactataattttt
11	5	C 101 T		104.	Ttccattgtttgcgatcaac
				105.	Ttccattgtttgctgatcaac
12	5	A 198 C	Lys 430 Gln	106.	Gaatgcattgaagagagtaat
				107.	Gaatgcattgcagagagtaat
13	6	A 197 G		108.	Ctggctgtgtggcaactgtga
				109.	Ctggctgtgtggcgactgtga
14	6	C 528 A		110.	Taagataaagccttatgag
				111.	Taagataaagacttatgag

Example 3

Genotyping UGT2B15

Sequencing and analysis were performed as described in Example 2. The amplification primers are provided in Table 9, the sequencing primers in Table 8, and the polymorphisms in Table 10.

Table 8
Sequencing Primers UGT2B15

Region		SEQ ID NO	Primer Sequence
UGT2B15 Exon 1	Primary F	119.	catgcacctattcagactgt
	Primary R	120.	tgggtgtcctgtagtagta
	Secondary F	121.	attgattttcctcagatataagta
	Secondary R	122.	tcataattccctaaaaaacac
UGT2B15 Exon 2	Primary F	123.	atatgtttgggtatgtattcc
	Primary R	124.	ccatattcccctcactct
	Secondary F	125.	atacctgcatattcaataacaa
	Secondary R	126.	tatccagccattcctct
UGT2B15 Exon 5	Primary F	127.	agtttttgggtataatgttac
	Primary R	128.	aaacgggtaaaaattcata
	Secondary F	129.	tcataccttgtaattaataatttg
	Secondary R	130.	cgggttaaaattcatattca
UGT2B15 Exon 6	Primary F	131.	tcatgccaatcagtgac
	Primary R	132.	accctccatgctgaaat
	Secondary F	133.	tcaaagaccatccatagactt
	Secondary R	134.	ggagtcctcatcttcagtc

Table 9
PCR Primers UGT2B15

P. No.	F/R	SEQ ID NO	Primer Sequence
1,2	F	135.	Attgattttcctcagatataagta
	R	136.	Attactggcatigacaag
3	F	137.	Attgattttcctcagatataagta
	R	138.	Tgtacagaaaggtatgttaa
4	F	139.	aaaaat g/t atttgaagattc
	R	140.	Tcataatttccctaaaaacac
5	F	141.	Atacctgcatattcaataacaa
	R	142.	Tatccagccattccttct
6,7	F	143.	Tcatacctgttaattaataatttg
	R	144.	Cgggtaaaattcatattca
8,9	F	145.	Tcaaagaccatccatagactt
	R	146.	Ggagtcccatcttcagtc

Table 10
Summary of Sequence Polymorphisms UGT2B15

N	Exon	Ntd change	AA change	SEQ ID NO.	Sequence
1	1	A 53 G	Ser 15 Gly	147.	tgatacagctcagttgttac
				148.	tgatacagctcggttgttac
2	1	T 184 G		149.	tgtagacatctcggcttct
				150.	tgtagacatcgtcggcttct
3	1	G 263 T	Asp 85 Tyr	151.	ctttaactaaaaatgatttgaa
				152.	ctttaactaaaaattatttgaa
4	1	T 519 C	Leu 170 Pro	153.	ttaacataccctttctgtaca
				154.	ttaacataccctttccgtaca
5	2	C 122 G	His 282 Gln	155.	tggaggacttcactgtaaacc
				156.	tggaggacttcagtgtaaacc
6	5	G 59 A		157.	tatgaggcgatctaccatgggat
				158.	tatgaggcaatctaccatgggat
7	5	C 100 T	Ala 398 Val	159.	ccctgtttgcggatcaacatgat
				160.	ccctgtttgtggatcaacatgat
8	6	G 14 A	Val 443 Ile	161.	aaagagaatgcatgaaattat
				162.	aaagagaatatcatgaaattat
9	6	C 523 A	Thr 523 Lys	163.	gcttgccaaaacaggaaagaa
				164.	gcttgccaaaaaggaagaa

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims

5

10

15

20

25

30

35

40

45

50

55

What is Claimed is:

1. An isolated nucleic acid molecule comprising a UGT2B sequence polymorphism of SEQ ID NOs:25-38; 84-111 or 147-164, as part of other than a naturally occurring chromosome.

2. A nucleic acid probe for detection of UGT2B locus polymorphisms, comprising a polymorphic sequence of SEQ ID NOs:25-38; 84-111 or 147-164.

3. A nucleic acid probe according to Claim 2, wherein said probe is conjugated to a detectable marker.

4. An array of oligonucleotides comprising:
two or more probes for detection of UGT2B locus polymorphisms, said probes comprising at least one form of a polymorphic sequences of SEQ ID NOs:25-38; 84-111 or 147-164.

5. A method for detecting in an individual a polymorphism in a UGT2B metabolism of a substrate, the method comprising:

analyzing the genome of said individual for the presence of at least one UGT2B polymorphism of SEQ ID NOs:25-38; 84-111 or 147-164; wherein the presence of said predisposing polymorphism is indicative of an alteration in UGT2B expression or activity.

6. A method according to Claim 5, wherein said analyzing step comprises detection of specific binding between the genomic DNA of said individual with an array of oligonucleotides comprising:

two or more probes for detection of UGT2B locus polymorphisms, said probes comprising at least one form of a polymorphic sequence of SEQ ID NOs:25-38; 84-111 or 147-164.

7. A method according to Claim 5, wherein said alteration in UGT2B expression is tissue specific.

8. A method according to Claim 5, wherein said alteration in UGT2B expression is in response to a UGT2B modifier.

5

9. A method according to Claim 8, wherein said modifier induces UGT2B expression.

10

5 10. A method according to Claim 8, wherein said modifier inhibits UGT2B expression.

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

<110> Penny, Laura
Galvin, Margaret
Miller, Andrew
Reidy, Michael

<120> Genotyping Human
UDP-Glucuronosyltransferase 2B4 (UGT2B4), 2B7 (UGT2B7) and
2B15 (UGT2B15) Genes

<130> SEQ-22PRV2

<160> 164

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1323

<212> DNA

<213> H. sapiens

<220>

<221> Other

<222> (140)...(897)

<400> 1

tcactacct	tttagttg	tctttgtcat	ccacatgctc	agactgttaa	tataatgtat	60
ttactttgaa	gtgtaaaagt	tacattttta	cttcttgact	gatttatact	ggatgtcacc	120
atgagaaatg	acagaaagga	gcagcaactg	gaaaacaagc	attgcattgc	atcaggatgt	180
ctatgaaatg	gacttcagct	cttctgctga	tacagctgag	ctgttacttt	agctctggga	240
gttggtgaaa	gggtgctggg	tggccacacg	aattcagcca	ctggatgaat	ataaagacaa	300
tcctggatga	acttgtccag	agaggtcatg	aggtgactgt	attggcatct	tcagcttcca	360
tttcttttga	tcaccaacagc	ccatctactc	ttaaatttga	agtttatcct	gtatctttta	420
ctaaaactga	gtttgaggat	attatcaagc	agctggttta	gagatgggca	gaacttccaa	480
aagacacatt	ttggtcatat	ttttcacaag	tacaagaaat	catgtggaca	tttaatgaca	540
tacttagaaa	gttctgtaag	gatatagttt	caaataagaa	acttatgaag	aaactacagg	600
agtcaagatt	tgatgttggt	cttgcatatg	ctgttttccc	ctttggtag	ctgctggccg	660
agttacttaa	aatacccttt	gtctacagcc	tcctgttctc	tcctggctac	gcaattgaaa	720
agcatagtgg	aggacttctg	ttccctcctt	cctatgtgcc	tggtgttatg	tcagaactaa	780
gtgaccaaat	gactttcata	gagagggtta	aaaatatgat	ctatgtgctt	tattttgaat	840
tttggttcca	aattattgac	atgaagaagt	gggatcagtt	ctacagtga	gttctaggta	900
agtaactttt	ttgattggta	acatgaagat	ctaactttct	tgtacctttg	aagctgagtt	960
tgtaataagc	cataaagtca	gggtagtggg	gtatttttgt	aatgaattta	tcaaatgaaa	1020
ttgtaagatg	atctaccaaa	ctcacaaagc	ctatagaaaa	tgtaaatatt	aggatcagtt	1080
aaaactctgt	ggccatcact	catacagaag	actccaggaa	gtcataagcc	tgtatatatt	1140
tgccactaag	atttctttta	gcaatcacat	atctgtttta	ttatacattt	tttcatctta	1200
aaaaaaagtc	agacttattc	agaaacatct	tgctgaatgc	atactggtag	attgagtagt	1260
tcacacattt	ttagaactat	ctataataca	ttgcagaaat	tgttttttct	tgtatatatt	1320
cag						1323

<210> 2

<211> 746

<212> DNA

<213> H. sapiens

<220>

<221> Other
<222> (195)...(344)

<400> 2

ttcttgtaaa	tacacatggg	taaaatatat	aatacataaa	aattaaatta	tgccatatata	60
ogaatatatg	tatttttttt	caaggcacaa	acactttggc	tacatttttg	cccacattat	120
tctaactctt	ttcagaaaat	tacctagttt	aattatcttg	tgcatctctat	cttttctttt	180
tttttcccc	atcaggaaga	cccactacgt	tatctgagac	aatggcaaaa	gctgacatat	240
ggcttattcg	aaactactgg	gattttcaat	ttcctcacc	actcttacca	aatgttgagt	300
tcgttggagg	actccactgc	aaacctgcca	aacccctacc	gaaggtaaac	tattactgtt	360
tgttttgtct	gctttgaagt	ttcagtaaga	atggttctat	attcattcaa	agtgtttgac	420
ttacactgga	agaaaggtgg	aagtgggaag	agtaaagcag	ataccaatta	gaaactgacg	480
tacatgttga	tactatcaca	agtttatgaa	tttcatcatt	attaccaata	aagagggata	540
ctaaagagac	tttgaataa	gggttggtaa	attaaagctt	tgattatgca	acataataga	600
aggtactggc	cattcattca	aagaatattt	ataaagagat	tagcacacac	cacaggtagc	660
tgtaggggac	acagtttcta	tcocaacaca	ccttacattc	tattttgaaa	gatagaatat	720
atgcaagtaa	taaaaactgt	gtaaaa				746

<210> 3
<211> 785
<212> DNA
<213> H. sapiens

<220>
<221> Other
<222> (238)...(369)

<400> 3

ttcacaaacg	cacacacata	cacacacaca	tatttacaca	aagaccctta	acagaggcaa	60
cctatctcat	attatacata	ttgcaaaaaa	aactgagtaa	ttgagtcagt	taaaaaacat	120
cctttactoc	aataattcct	gataaaaactt	gattttctct	ctttttataa	caattctttc	180
acagtgtgtg	ctgtgtctgat	aatctattat	gatagaacaa	attctttttt	ttcacaggaa	240
atggaagagt	ttgtccagag	ctctggagaa	aatgggtgtg	tggtgttttc	ctgtgggtcg	300
atggtcagta	acacgtcaga	agaaagggcc	aatgtaattg	catcagccct	tgccaagatc	360
ccacaaaagg	taagataaaa	tgttttaatg	gtgtaaaaaa	ctactgaaag	aggctgttaa	420
agtttgtaaa	gaaccaatt	gtagaaaactt	cctgcctata	tattcagctg	ttgggaagc	480
actaattatc	tcagatatta	attcaaaato	aaaaatatgt	atggaagatg	ataaactcat	540
acagaagggtg	tttttcattg	gtaattaatt	tggcattaat	attgtgatca	ggaataaata	600
caattaagag	ttgcaggtaa	agtttttgta	ttatcatgat	actgggttca	ggttaagagct	660
atcacaaaat	tctgccctcg	tgatttgatc	cttttgttta	agaactcctg	agggcgatgt	720
acatcctaca	ggtgtagaa	aacgttacat	tttaatgagt	aacttcacta	gcacaataac	780
aatag						785

<210> 4
<211> 1138
<212> DNA
<213> H. sapiens

<220>
<221> Other
<222> (395)...(482)

<400> 4

catctgttat	tttttgagtt	tttaataatg	gccattctga	ctggtgtgag	atgggtatctc	60
tttgtggatt	taaccagtga	tgtaaacctt	tttttcatat	agtgggttgc	cacatatagt	120
tttcttttga	aaagtgtaac	aactttttta	atacttgaac	ttttcattga	ttatctttat	180
tgtctaagct	actattttga	aaaatcatga	tttctttata	tacctaatga	tgaatttaag	240
gaaatgaaat	atgagtattc	tatttacatc	agtctgagta	gttcttggta	cttaacatcc	300
cttgttcttc	tcattgttaa	tctctttaga	tttctaacat	tctatgactt	ttgagttcca	360
ctcatggaat	aagatatattt	cttcaactga	acaggttctg	tggagatttg	atgggaataa	420
accagatact	ttaggactca	atactcggct	gtacaagtgg	ataccccgaga	atgatcttct	480
tggttaagtct	ctgaagaaca	aatactgaat	atattagtaa	cagattatta	aagtgttaat	540

WO 00/06776

PCT/US99/16675

agctatcatg	aaacaagctt	actgaacatt	tggtatggaa	aaacttaaaa	ataaaatgaa	600
acttccttat	attttatttc	cagtcctggg	ggaaaagaat	aaattgttgg	cattttatga	660
tatgcaccca	catttctttac	aatcagagtc	agagtatcct	tatttcaggt	gttattacot	720
cccacagaat	ttttctggca	cttcctgggt	tgtcttcctt	tctcatattt	ctacaacttt	780
acacctgttc	tttctctctc	tgtaggggtt	tttcaaatgt	cactaaaagt	aacagctcct	840
ctgctatcac	cagggatgct	gcattttctg	taggattaaa	tcctaatct	taatcaaaaa	900
gtgatgacac	atttcataat	gaaatgtgac	ctgtctttcc	tcaattctag	caccaccacc	960
acctcactgc	ctgctgcctt	gcacacccta	catatccaac	tccgtgactg	tacttaagag	1020
aacacattct	ggctgggcac	ggtgctcacg	cctgcaatcc	tagcactttg	ggaggctgat	1080
ggcaggtgga	ttgactgagc	tcaggagtcc	aagaccatcc	tgggcaacat	ggtgaaac	1138

<210> 5
 <211> 689
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (123)... (342)

<400> 5						
aaaaacaatt	ttaattcagt	tcagtgtgtt	atctaggaaa	caccgtcaca	ttcagattct	60
tccattgtgc	atttctcatt	ttattcctat	gaataatttt	gctaaaattc	atccaatcct	120
aggctaccca	aaaaccagag	cttttataac	tcatgggtgga	gccaatggca	tctatgaggg	180
aatctaccat	ggaatcccta	tggtgggcgt	tccattgttt	gcagatcaac	ctgataaacat	240
tgcacacatg	aaggccaagg	gagcagctgt	tagtttggac	ttccacacaa	tgctcgagtac	300
agactttact	aatgcactga	agacagtaat	taatgatcct	ttgtgagtat	aacttttttt	360
ttactcgggtg	gtctttatag	ataggttcc	ttgtgaatag	tgagtatgac	ttttatcctt	420
tttataagcg	actgatttcc	aaagaattta	agtgtattta	acaatctgaa	atctgtcttt	480
atttttgagt	ggttatttta	aaattttatt	tgaaccacat	acattttaatg	aataatcaat	540
tattgaaata	attttctaca	caaaaataat	tttaaagtga	tatagataag	aagacatttt	600
aaaataaatt	tgacgtaatc	aatccacagt	agaaaggaaa	gataaacttg	acgtaatata	660
ataaaatatt	ttaattcaat	atctaaaaat				689

<210> 6
 <211> 1589
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (731)... (1475)

<400> 6						
atgcttaagc	aatgggtagc	ctttcttcat	gatgtgatta	tttcacactg	cagcctgtat	60
caaaacatct	catgcacctc	atagaaaaat	accctacta	tgtaaccaca	aaaactaaaa	120
attaaaaaga	aataaaattg	ctcatatgtt	ctctgcctca	aataattaac	tttctcacct	180
gacctcccat	ttttacttta	aaaatatttg	tcaattatga	aattccaatt	taaaagccaa	240
actttctatg	atgactcaaa	ttaaaataca	cacattctat	gtcaattcta	tgacattttac	300
tttgaatgat	ctggcacttt	aaaaaccttt	cgtggacttg	atgtgctcag	gcaaattaac	360
ttaccttctc	tttttttgag	agggaagtct	cactctgtca	ccaggctgga	gtgcagtggg	420
gtgattgtgg	ctcactgcaa	cttccgcctc	ttgggttcaa	gogattctcc	tgccctcagcc	480
tctcaagtag	ctgggactac	aggcacatgc	caccacgcct	gggtaattct	tttttttttt	540
ttttttttca	tatttttact	ggagacgggg	tgaacggggg	ttcaccgtgt	tagccaggat	600
ggtcttgatc	tcttgacctc	gtgatccgcc	cgcctcgacc	tcggaaagtg	ctgggattgc	660
aggtgtgagc	ctccgtgcct	ggccaaattg	acttactttc	aatgttgata	cttttctgct	720
tatcgtttag	atataaaagag	aatgctatga	aattatcaag	aattcatcat	gatcaaccag	780
tgaagccctc	tgatcgagca	gtctttctga	ttgaatttgt	catgcgccat	aaaggagcca	840
agcaccttcg	ggttgacgcc	cacgacctca	cctggttcca	gtaccactct	ttggatgtga	900
ctgggttcct	gctggcctgt	gtggcaactg	tgatattcat	catcacaaaa	tgtctgtttt	960
gtgtctggaa	gtttgttaga	acaggaaga	aggggaaaag	agattaatta	cgtctgaggg	1020
tggaagctgg	gaaacccaat	aaatgaactc	cttttagtta	ttacaacaag	aagacgttgt	1080

PCT/US99/16675

```
<210> 7
<211> 2092
<212> DNA
<213> H. sapiens

<220>
<221> CDS
<222> {38}...{1621}
```

<400> 7																					
agc	gag	caa	act	gga	aaa	aac	aag	catt	gc	catt	g	cat	cag		atg	tct	atg	aaa	tgg	act	55
Met	Ser	Met	Lys												1	Ser	Met	Lys	Trp	Thr	
tca	gct	ctt	ctg	ctg	ata	cag	ctg	agc	tgt	tac	ttt	agc	tct	ggg	agt						103
Ser	Ala	Leu	Leu	Leu	Ile	Gln	Leu	Ser	Cys	Tyr	Phe	Ser	Ser	Gly	Ser						
			10						15				20								
tgt	gga	aag	gtg	ctg	gtg	tgg	ccc	aca	gaa	ttc	agc	cac	tgg	atg	aat						151
Cys	Gly	Lys	Val	Leu	Val	Trp	Pro	Thr	Glu	Phe	Ser	His	Trp	Met	Asn						
		25					30					35									
ata	aag	aca	atc	ctg	gat	gaa	ctt	gtc	cag	aga	ggc	cat	gag	gtg	act						199
Ile	Lys	Thr	Ile	Leu	Asp	Glu	Leu	Val	Gln	Arg	Gly	His	Glu	Val	Thr						
		40				45					50										
gta	ttg	gca	tct	tca	gct	tcc	att	tct	ttc	gat	ccc	aac	agc	cca	tct						247
Val	Leu	Ala	Ser	Ser	Ala	Ser	Ile	Ser	Phe	Asp	Pro	Asn	Ser	Pro	Ser						
		55			60					65				70							
act	ctt	aaa	ttt	gaa	gtt	tat	cot	gta	tct	tta	act	aaa	act	gag	ttt						295
Thr	Leu	Lys	Phe	Glu	Val	Tyr	Pro	Val	Ser	Leu	Thr	Lys	Thr	Glu	Phe						
				75					80					85							
gag	gat	att	atc	aag	cag	ctg	gtt	aag	aga	tgg	gca	gaa	ctt	cca	aaa						343
Glu	Asp	Ile	Ile	Lys	Gln	Leu	Val	Lys	Arg	Trp	Ala	Glu	Leu	Pro	Lys						
			90						95				100								
gac	aca	ttt	tgg	tca	tat	ttt	tca	caa	gta	caa	gaa	atc	atg	tgg	aca						391
Asp	Thr	Phe	Trp	Ser	Tyr	Phe	Ser	Gln	Val	Gln	Glu	Ile	Met	Trp	Thr						
		105				110						115									
ttt	aat	gac	ata	ctt	aga	aag	ttc	tgt	aag	gat	ata	gtt	tca	aat	aag						439
Phe	Asn	Asp	Ile	Leu	Arg	Lys	Phe	Cys	Lys	Asp	Ile	Val	Ser	Asn	Lys						
		120				125					130										
aaa	ctt	atg	aag	aaa	cta	cag	gag	tca	aga	ttt	gat	gtt	gtt	ctt	gca						487
Lys	Leu	Met	Lys	Lys	Leu	Gln	Glu	Ser	Arg	Phe	Asp	Val	Val	Leu	Ala						
		135			140					145					150						
gat	gct	gtt	ttc	ccc	ttt	ggt	gag	ctg	ctg	gcc	gag	tta	ctt	aaa	ata						535
Asp	Ala	Val	Phe	Pro	Phe	Gly	Glu	Leu	Leu	Ala	Glu	Leu									

WO 00/06776

PCT/US99/16675

	155	160	165	
ccc ttt gtc tac agc ctc cgc ttc tct cct ggc tac gca att gaa aag				583
Pro Phe Val Tyr Ser Leu Arg Phe Ser Pro Gly Tyr Ala Ile Glu Lys				
	170	175	180	
cat agt gga gga ctt ctg ttc cct cct tcc tat gtg cct gtt gtt atg				631
His Ser Gly Gly Leu Leu Phe Pro Pro Ser Tyr Val Pro Val Val Met				
	185	190	195	
tca gaa cta agt gac caa atg act ttc ata gag agg gta aaa aat atg				679
Ser Glu Leu Ser Asp Gln Met Thr Phe Ile Glu Arg Val Lys Asn Met				
	200	205	210	
atc tat gtg ctt tat ttt gaa ttt tgg ttc caa ata ttt gac atg aag				727
Ile Tyr Val Leu Tyr Phe Glu Phe Trp Phe Gln Ile Phe Asp Met Lys				
	215	220	225	230
aag tgg gat cag ttc tac agt gaa gtt cta gga aga ccc act acg tta				775
Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu Gly Arg Pro Thr Thr Leu				
	235	240	245	
tct gag aca atg gca aaa gct gac ata tgg ctt att cga aac tac tgg				823
Ser Glu Thr Met Ala Lys Ala Asp Ile Trp Leu Ile Arg Asn Tyr Trp				
	250	255	260	
gat ttt caa ttt cct cac cca ctc tta cca aat gtt gag ttc gtt gga				871
Asp Phe Gln Phe Pro His Pro Leu Leu Pro Asn Val Glu Phe Val Gly				
	265	270	275	
gga ctc cac tgc aaa cct gcc aaa ccc cta ccg aag gaa atg gaa gag				919
Gly Leu His Cys Lys Pro Ala Lys Pro Leu Pro Lys Glu Met Glu Glu				
	280	285	290	
ttt gtc cag agc tct gga gaa aat ggt gtt gtg gtg ttt tct ctg ggg				967
Phe Val Gln Ser Ser Gly Glu Asn Gly Val Val Val Phe Ser Leu Gly				
	295	300	305	310
tcg atg gtc agt aac acg tca gaa gaa agg gcc aat gta att gca tca				1015
Ser Met Val Ser Asn Thr Ser Glu Glu Arg Ala Asn Val Ile Ala Ser				
	315	320	325	
gcc ctt gcc aag atc cca caa aag gtt ctg tgg aga ttt gat ggg aat				1063
Ala Leu Ala Lys Ile Pro Gln Lys Val Leu Trp Arg Phe Asp Gly Asn				
	330	335	340	
aaa cca gat act tta gga ctc aat act cgg ctg tac aag tgg ata ccc				1111
Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg Leu Tyr Lys Trp Ile Pro				
	345	350	355	
cag aat gat ctt ctt ggt cac cca aaa acc aga gct ttt ata act cat				1159
Gln Asn Asp Leu Leu Gly His Pro Lys Thr Arg Ala Phe Ile Thr His				
	360	365	370	
ggt gga gcc aat ggc atc tat gag gca atc tac cat gga atc cct atg				1207
Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile Tyr His Gly Ile Pro Met				
	375	380	385	390
gtg ggc gtt cca ttg ttt gca gat caa cct gat aac att gca cac atg				1255
Val Gly Val Pro Leu Phe Ala Asp Gln Pro Asp Asn Ile Ala His Met				
	395	400	405	

WO 00/06776

PCT/US99/16675

aag gcc aag gga gca gct gtt agt ttg gac ttc cac aca atg tcg agt 1303
 Lys Ala Lys Gly Ala Ala Val Ser Leu Asp Phe His Thr Met Ser Ser
 410 415 420
 aca gac tta ctc aat gca ctg aag aca gta att aat gat cct tta tat 1351
 Thr Asp Leu Leu Asn Ala Leu Lys Thr Val Ile Asn Asp Pro Leu Tyr
 425 430 435
 aaa gag aat gct atg aaa tta tca aga att cat cat gat caa cca gtg 1399
 Lys Glu Asn Ala Met Lys Leu Ser Arg Ile His His Asp Gln Pro Val
 440 445 450
 aag ccc ctt gat cga gca gtc ttc tgg att gaa ttt gtc atg cgc cat 1447
 Lys Pro Leu Asp Arg Ala Val Phe Trp Ile Glu Phe Val Met Arg His
 455 460 465 470
 aaa gga gcc aag cac ctt cgg gtt gca gcc cac gac ctc acc tgg ttc 1495
 Lys Gly Ala Lys His Leu Arg Val Ala Ala His Asp Leu Thr Trp Phe
 475 480 485
 cag tac cac tct ttg gat gtg act ggg ttc ctg ctg gcc tgt gtg gca 1543
 Gln Tyr His Ser Leu Asp Val Thr Gly Phe Leu Leu Ala Cys Val Ala
 490 495 500
 act gtg ata ttc atc atc aca aaa tgt ctg ttt tgt gtc tgg aag ttt 1591
 Thr Val Ile Phe Ile Ile Thr Lys Cys Leu Phe Cys Val Trp Lys Phe
 505 510 515
 gtt aga aca gga aag aag ggg aaa aga gat taattacgtc tgaggctgga 1641
 Val Arg Thr Gly Lys Lys Gly Lys Arg Asp
 520 525
 agctgggaaa cccaataaat gaactccttt agtttattac aacaagaaga cgttgtgata 1701
 caagagattc ctttcttctt gtgacaaaac atctttcaaa acttaccttg tcaagtcaaa 1761
 atttgtttta gtacctgttt aaccattaga aatatttcat gtcaaggagg aaaacattag 1821
 ggaaaacaaa aatgatataa agccatacga ggttatattg aaatgtattg agcttatatt 1881
 gaaatttatt gttccaattc acagggttaca tgaaaaaaa tttactaagc ttaactacatt 1941
 gtcacacatt gtacatggaa acaagaacat taagaagtcc actgacagta tcagtactgt 2001
 tttgcaataa ctcagcatac ttggatcca ttcatgcag gattgtgttg ttttaactgt 2061
 tgttgaggaa actaataaat aattaaattg t 2092

<210> 8

<211> 528

<212> PRT

<213> H. sapiens

<400> 8

Met Ser Met Lys Trp Thr Ser Ala Leu Leu Leu Ile Gln Leu Ser Cys
 1 5 10 15
 Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu
 20 25 30
 Phe Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp Glu Leu Val Gln
 35 40 45
 Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile Ser Phe
 50 55 60
 Asp Pro Asn Ser Pro Ser Thr Leu Lys Phe Glu Val Tyr Pro Val Ser
 65 70 75 80
 Leu Thr Lys Thr Glu Phe Glu Asp Ile Ile Lys Gln Leu Val Lys Arg
 85 90 95
 Trp Ala Glu Leu Pro Lys Asp Thr Phe Trp Ser Tyr Phe Ser Gln Val
 100 105 110
 Gln Glu Ile Met Trp Thr Phe Asn Asp Ile Leu Arg Lys Phe Cys Lys

WO 00/06776

PCT/US99/16675

```

115      120      125
Asp Ile Val Ser Asn Lys Lys Leu Met Lys Lys Leu Gln Glu Ser Arg
130      135      140
Phe Asp Val Val Leu Ala Asp Ala Val Phe Pro Phe Gly Glu Leu Leu
145      150      155
Ala Glu Leu Leu Lys Ile Pro Phe Val Tyr Ser Leu Arg Phe Ser Pro
165      170      175
Gly Tyr Ala Ile Glu Lys His Ser Gly Gly Leu Leu Phe Pro Pro Ser
180      185      190
Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Thr Phe Ile
195      200      205
Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Glu Phe Trp Phe
210      215      220
Gln Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu
225      230      235
Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Ala Lys Ala Asp Ile Trp
245      250      255
Leu Ile Arg Asn Tyr Trp Asp Phe Gln Phe Pro His Pro Leu Leu Pro
260      265      270
Asn Val Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro Leu
275      280      285
Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly Val
290      295      300
Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Thr Ser Glu Glu Arg
305      310      315
Ala Asn Val Ile Ala Ser Ala Leu Ala Lys Ile Pro Gln Lys Val Leu
325      330      335
Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg
340      345      350
Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
355      360      365
Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile
370      375      380
Tyr His Gly Ile Pro Met Val Gly Val Pro Leu Phe Ala Asp Gln Pro
385      390      395
Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Ser Leu Asp
405      410      415
Phe His Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu Lys Thr Val
420      425      430
Ile Asn Asp Pro Leu Tyr Lys Glu Asn Ala Met Lys Leu Ser Arg Ile
435      440      445
His His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile
450      455      460
Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala Ala
465      470      475
His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp Val Thr Gly Phe
485      490      495
Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Cys Leu
500      505      510
Phe Cys Val Trp Lys Phe Val Arg Thr Gly Lys Lys Gly Lys Arg Asp
515      520      525

```

<210> 9
 <211> 24
 <212> DNA
 <213> H. sapiens

<400> 9
 taccttttag ttgtctcttt gtca

<210> 10
 <211> 21

24

WO 00/06776

PCT/US99/16675

<212> DNA	
<213> H. sapiens	
<400> 10	
ttcctggagt cttctgtatg a	21
<210> 11	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 11	
catcccttgt tcttctcatt	20
<210> 12	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 12	
cgggactgga aaataaatat	20
<210> 13	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 13	
ggggtttcac cgtgtta	17
<210> 14	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 14	
aaagccaagc agcactaa	18
<210> 15	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 15	
ccacatgctc agactgttaa	20
<210> 16	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 16	
caaaaataacc ccactaccc	19
<210> 17	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 17	
cccttggtct tctcattgtt a	21

WO 00/06776

PCT/US99/16675

<210> 18	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 18	
ttcagtaagc ttgtttcatg at	22
<210> 19	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 19	
cctggccaaa ttgactt	17
<210> 20	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 20	
caggaaccca gtcacatc	18
<210> 21	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 21	
ggggaaaaga gattaattac g	21
<210> 22	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 22	
agccaagcag cactaatc	18
<210> 23	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 23	
tccaattcac aggttacatg	20
<210> 24	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 24	
agccaagcag cactaatc	18
<210> 25	
<211> 27	
<212> DNA	
<213> H. sapiens	
<400> 25	

WO 00/06776

PCT/US99/16675

tggatgaata taaagacaat cctggat

27

<210> 26
<211> 27
<212> DNA
<213> H. sapiens

<400> 26

tggatgaata taaacacaat cctggat

27

<210> 27
<211> 27
<212> DNA
<213> H. sapiens

<400> 27

aagtgttaat agttatcatg aaacaag

27

<210> 28
<211> 27
<212> DNA
<213> H. sapiens

<400> 28

aagtgttaat agctatcatg aaacaag

27

<210> 29
<211> 27
<212> DNA
<213> H. sapiens

<400> 29

tgaagcccct tgatcgagca gtcttct

27

<210> 30
<211> 27
<212> DNA
<213> H. sapiens

<400> 30

tgaagcccct tgaacgagca gtcttct

27

<210> 31
<211> 27
<212> DNA
<213> H. sapiens

<400> 31

tgaagcccct tgatcgagca gtcttct

27

<210> 32
<211> 27
<212> DNA
<213> H. sapiens

<400> 32

tgaagcccct tgatagagca gtcttct

27

<210> 33
<211> 27
<212> DNA
<213> H. sapiens

WO 00/06776

PCT/US99/16675

```

<400> 33
gatataaagc catacgaggt tatattg                27

<210> 34
<211> 27
<212> DNA
<213> H. sapiens

<400> 34
gatataaagc catatgaggt tatattg                27

<210> 35
<211> 26
<212> DNA
<213> H. sapiens

<400> 35
caggttacat gaaaaaaat ttacta                26

<210> 36
<211> 26
<212> DNA
<213> H. sapiens

<400> 36
caggttacat gaaaaacaat ttacta                26

<210> 37
<211> 27
<212> DNA
<213> H. sapiens

<400> 37
ttgttgagga agctaataaa taattaa                27

<210> 38
<211> 27
<212> DNA
<213> H. sapiens

<400> 38
ttgttgagga aactaataaa taattaa                27

<210> 39
<211> 1854
<212> DNA
<213> H. sapiens

<220>
<221> CDS
<222> (15)...(1584)

<400> 39
tgcattgcac cagg atg tct gtg aaa tgg act tca gta att ttg cta ata    50
          Met Ser Val Lys Trp Thr Ser Val Ile Leu Leu Ile
          1          5          10

caa ctg agc ttt tgc ttt agc tct ggg aat tgt gga aag gtg ctg gtg    98
Gln Leu Ser Phe Cys Phe Ser Ser Gly Asn Cys Gly Lys Val Leu Val
          15          20          25

```

WO 00/06776

PCT/US99/16675

tgg gca gca gaa tac agc cat tgg atg aat ata aag aca atc ctg gat	146
Trp Ala Ala Glu Tyr Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp	
30 35 40	
gag ctt att cag aga ggt cat gag gtg act gta ctg gca tct tca got	194
Glu Leu Ile Gln Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala	
45 50 55 60	
tcc att ctt ttt gat ccc aac aac tca tcc gct ctt aaa att gaa att	242
Ser Ile Leu Phe Asp Pro Asn Asn Ser Ser Ala Leu Lys Ile Glu Ile	
65 70 75	
tat ccc aca tct tta act aaa act gag ttg gag aat ttc atc atg caa	290
Tyr Pro Thr Ser Leu Thr Lys Thr Glu Leu Glu Asn Phe Ile Met Gln	
80 85 90	
cag att aag aga tgg tca gac ctt cca aaa gat aca ttt tgg tta tat	338
Gln Ile Lys Arg Trp Ser Asp Leu Pro Lys Asp Thr Phe Trp Leu Tyr	
95 100 105	
ttt tca caa gta cag gaa atc atg tca ata ttt ggt gac ata act aga	386
Phe Ser Gln Val Gln Glu Ile Met Ser Ile Phe Gly Asp Ile Thr Arg	
110 115 120	
aag ttc tgt aaa gat gta gtt tca aat aag aaa ttt atg aaa gta	434
Lys Phe Cys Lys Asp Val Val Ser Asn Lys Lys Phe Met Lys Lys Val	
125 130 135 140	
caa gag tca aga ttt gac gtc att ttt gca gat gct att ttt ccc tgt	482
Gln Glu Ser Arg Phe Asp Val Ile Phe Ala Asp Ala Ile Phe Pro Cys	
145 150 155	
agt gag ctg ctg gct gag cta ttt aac ata ccc ttt gtg tac agt ctc	530
Ser Glu Leu Leu Ala Glu Leu Phe Asn Ile Pro Phe Val Tyr Ser Leu	
160 165 170	
agc ttc tct cct ggc tac act ttt gaa aag cat agt gga gga ttt att	578
Ser Phe Ser Pro Gly Tyr Thr Phe Glu Lys His Ser Gly Gly Phe Ile	
175 180 185	
ttc cct cct tcc tac gta cct gtt gtt atg tca gaa tta act gat caa	626
Phe Pro Pro Ser Tyr Val Pro Val Val Met Ser Glu Leu Thr Asp Gln	
190 195 200	
atg act ttc atg gag agg gta aaa aat atg atc tat gtg ctt tac ttt	674
Met Thr Phe Met Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe	
205 210 215 220	
gac ttt tgg ttc gaa ata ttt gac atg aag aag tgg gat cag ttt tat	722
Asp Phe Trp Phe Glu Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr	
225 230 235	
agt gaa gtt cta gga aga ccc act aca tta tct gag aca atg ggg aaa	770
Ser Glu Val Leu Glu Arg Pro Thr Thr Leu Ser Glu Thr Met Gly Lys	
240 245 250	
gct gac gta tgg ctt att cga aac tcc tgg aat ttt cag ttt cca tat	818
Ala Asp Val Trp Leu Ile Arg Asn Ser Trp Asn Phe Gln Phe Pro Tyr	
255 260 265	
cca ctc tta cca aat gtt gat ttt gtt gga gga ctc cac tgc aaa cct	866
Pro Leu Leu Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro	

WO 00/06776

PCT/US99/16675

270	275	280	
gcc aaa ccc ctg cct aag gaa atg gaa gac ttt gta cag agc tct gga Ala Lys Pro Leu Pro Lys Glu Met Glu Asp Phe Val Gln Ser Ser Gly 285 290 295 300			914
gaa aat ggt gtt gtg gtg ttt tct ctg ggg tca atg gtc agt aac atg Glu Asn Gly Val Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Met 305 310 315			962
aca gaa gaa agg gcc aac gta att gca tca gcc ctg gcc cag atc cca Thr Glu Glu Arg Ala Asn Val Ile Ala Ser Ala Leu Ala Gln Ile Pro 320 325 330			1010
caa aag gtt ctg tgg aga ttt gat ggg aat aaa cca gat acc tta ggt Gln Lys Val Leu Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly 335 340 345			1058
ctc aat act cgg ctc tac aag tgg ata ccc cag aat gac ctt cta ggt Leu Asn Thr Arg Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly 350 355 360			1106
cat cca aag acc aga gct ttt ata act cat ggt gga gcc aat ggc atc His Pro Lys Thr Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile 365 370 375 380			1154
tac gag gca atc tac cat ggg atc cct atg gtg ggg att cca ttg ttt Tyr Glu Ala Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe 385 390 395			1202
gcc gat caa cct gat aac att gct cac atg aag gcc agg gga gca gct Ala Asp Gln Pro Asp Asn Ile Ala His Met Lys Ala Arg Gly Ala Ala 400 405 410			1250
gtt aga gtg gac ttc aac aca atg tgc agt aca gac ttg ctg aat gca Val Arg Val Asp Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala 415 420 425			1298
ttg aag aga gta att aat gat cct tca tat aaa gag aat gtt atg aaa Leu Lys Arg Val Ile Asn Asp Pro Ser Tyr Lys Glu Asn Val Met Lys 430 435 440			1346
tta tca aga att caa cat gat caa cca gtg aag ccc ctg gat cga gca Leu Ser Arg Ile Gln His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala 445 450 455 460			1394
gtc ttc tgg att gaa ttt gtc atg cgc cac aaa gga gct aaa cac ctt Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu 465 470 475			1442
cgg gtt gca gcc cac gac ctc acc tgg ttc cag tac cac tct ttg gat Arg Val Ala Ala His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp 480 485 490			1490
gtg att ggg ttc ctg ctg gtc tgt gtg gca act gtg ata ttt atc gtc Val Ile Gly Phe Leu Leu Val Cys Val Ala Thr Val Ile Phe Ile Val 495 500 505			1538
aca aaa tgt tgt ctg ttt tgt ttc tgg aag ttt gct aga aaa gca a Thr Lys Cys Cys Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Ala 510 515 520			1584

WO 00/06776

PCT/US99/16675

```

agaagggaaa aaatgattag ttatatctga gatttgaagc tggaaaacct gataggtgag 1644
actacttcag ttatttcag caagaaagat tgtgatgcaa gatttctttc ttcctgagac 1704
aaaaaaaaaa aaagaaaaaa aaatcttttc aaaatttact ttgtcaaata aaaatttggt 1764
tttcagagat ttaccaccca gtcatggtt agaaatattt tgtggcaatg aagaaaacac 1824
tacgaaaaat aaaaaataag ataaagcctt

```

<210> 40
 <211> 524
 <212> PRT
 <213> H. sapiens

<400> 40

Met	Ser	Val	Lys	Trp	Thr	Ser	Val	Ile	Leu	Leu	Ile	Gln	Leu	Ser	Phe
1			5						10				15		
Cys	Phe	Ser	Ser	Gly	Asn	Cys	Gly	Lys	Val	Leu	Val	Trp	Ala	Ala	Glu
			20					25					30		
Tyr	Ser	His	Trp	Met	Asn	Ile	Lys	Thr	Ile	Leu	Asp	Glu	Leu	Ile	Gln
			35				40					45			
Arg	Gly	His	Glu	Val	Thr	Val	Leu	Ala	Ser	Ser	Ala	Ser	Ile	Leu	Phe
	50					55					60				
Asp	Pro	Asn	Asn	Ser	Ser	Ala	Leu	Lys	Ile	Glu	Ile	Tyr	Pro	Thr	Ser
65						70				75				80	
Leu	Thr	Lys	Thr	Glu	Leu	Glu	Asn	Phe	Ile	Met	Gln	Gln	Ile	Lys	Arg
				85					90				95		
Trp	Ser	Asp	Leu	Pro	Lys	Asp	Thr	Phe	Trp	Leu	Tyr	Phe	Ser	Gln	Val
			100					105					110		
Gln	Glu	Ile	Met	Ser	Ile	Phe	Gly	Asp	Ile	Thr	Arg	Lys	Phe	Cys	Lys
			115				120					125			
Asp	Val	Val	Ser	Asn	Lys	Lys	Phe	Met	Lys	Lys	Val	Gln	Glu	Ser	Arg
			130				135					140			
Phe	Asp	Val	Ile	Phe	Ala	Asp	Ala	Ile	Phe	Pro	Cys	Ser	Glu	Leu	Leu
145					150					155				160	
Ala	Glu	Leu	Phe	Asn	Ile	Pro	Phe	Val	Tyr	Ser	Leu	Ser	Phe	Ser	Pro
				165					170				175		
Gly	Tyr	Thr	Phe	Glu	Lys	His	Ser	Gly	Gly	Phe	Ile	Phe	Pro	Pro	Ser
			180					185					190		
Tyr	Val	Pro	Val	Val	Met	Ser	Glu	Leu	Thr	Asp	Gln	Met	Thr	Phe	Met
			195				200					205			
Glu	Arg	Val	Lys	Asn	Met	Ile	Tyr	Val	Leu	Tyr	Phe	Asp	Phe	Trp	Phe
			210				215					220			
Glu	Ile	Phe	Asp	Met	Lys	Lys	Trp	Asp	Gln	Phe	Tyr	Ser	Glu	Val	Leu
225					230					235				240	
Gly	Arg	Pro	Thr	Thr	Leu	Ser	Glu	Thr	Met	Gly	Lys	Ala	Asp	Val	Trp
				245					250				255		
Leu	Ile	Arg	Asn	Ser	Trp	Asn	Phe	Gln	Phe	Pro	Tyr	Pro	Leu	Leu	Pro
			260				265						270		
Asn	Val	Asp	Phe	Val	Gly	Gly	Leu	His	Cys	Lys	Pro	Ala	Lys	Pro	Leu
			275				280					285			
Pro	Lys	Glu	Met	Glu	Asp	Phe	Val	Gln	Ser	Ser	Gly	Glu	Asn	Gly	Val
			290				295					300			
Val	Val	Phe	Ser	Leu	Gly	Ser	Met	Val	Ser	Asn	Met	Thr	Glu	Glu	Arg
305					310					315				320	
Ala	Asn	Val	Ile	Ala	Ser	Ala	Leu	Ala	Gln	Ile	Pro	Gln	Lys	Val	Leu
				325					330				335		
Trp	Arg	Phe	Asp	Gly	Asn	Lys	Pro	Asp	Thr	Leu	Gly	Leu	Asn	Thr	Arg
			340					345					350		
Leu	Tyr	Lys	Trp	Ile	Pro	Gln	Asn	Asp	Leu	Leu	Gly	His	Pro	Lys	Thr
			355				360					365			
Arg	Ala	Phe	Ile	Thr	His	Gly	Gly	Ala	Asn	Gly	Ile	Tyr	Glu	Ala	Ile
			370				375					380			
Tyr	His	Gly	Ile	Pro	Met	Val	Gly	Ile	Pro	Leu	Phe	Ala	Asp	Gln	Pro
385					390					395				400	

Asp Asn Ile Ala His Met Lys Ala Arg Gly Ala Ala Val Arg Val Asp
405 410 415
Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu Lys Arg Val
420 425 430
Ile Asn Asp Pro Ser Tyr Lys Glu Asn Val Met Lys Leu Ser Arg Ile
435 440 445
Gln His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile
450 455 460
Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala Ala
465 470 475 480
His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp Val Ile Gly Phe
485 490 495
Leu Leu Val Cys Val Ala Thr Val Ile Phe Ile Val Thr Lys Cys Cys
500 505 510
Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Ala Lys
515 520

<210> 41
<211> 1686
<212> DNA
<213> H. sapiens

<220>
<221> exon
<222> (392)... (1126)

<400> 41
tccccagttt cacaaaaata tgtggaccat gtttagtcat ttaatcttta gttttgtgtc 60
aaatggactg cagaaacaag atctgtcaact gctactgttc tggacactct tctaaaaatat 120
attgcataag acagatggca tgtccataca agatccttga tattagctga aggatagcac 180
tcataaacat aaaagggaaa ttaatcacat ctgtgtgaac agatcattta ccttcatttg 240
tctctttgoc atccacatgc tcagactggt gatttaatga tattgtatgt actttgactt 300
ataagggtta cattttaact tcttggctaa tttatctttg gacataacca tgagaaatga 360
cagaaaggaa cagcaactgg aaaacaagca ttgcattgca ccaggatgtc tgtgaaatgg 420
acttcagtaa ttttgctaata acaactgagc ttttgcttta gctctgggaa ttgtggaaag 480
gtgctggtgt gggcagcaga atacagccat tggatgaata taaagacaat cctggatgag 540
cttattcaga gaggtcatga ggtgactgta ctggcatctt cagcttccat tctttttgat 600
cccaacaact catccgctct taaaattgaa atttatccca catctttaac taaaactgag 660
ttggagaatt tcatcatgca acagattaag agatggtcag accttccaaa agatacattt 720
tggttatatt tttcacagt acaggaaatc atgtcaatat ttggtgacat aactagaaag 780
ttctgtaaa atgtagtctt aaataagaaa tttatgaaaa aagtacaaga gtcaagattt 840
gacgtcattt ttgcagatgc tatttttccc tgtagtgagc tgctggctga gctatttaac 900
ataccctttg tgtacagtct cagcttctct cctggctaca ctttgaaaa gcatagtgga 960
ggatttattt tccctccttc ctacgtacct gttgttatgt cagaattaac tgatcaaatg 1020
actttcatgg agagggtaaa aaatatgac tatgtgcttt actttgactt ttggttcgaa 1080
atatttgaca tgaagaagt ggatcagttt tatagtgaag ttctaggtaa gtattttttt 1140
caatcagtaa catgaagctc taacttattt gtgtctttga agcagagctt atataaagcc 1200
ataaagtcag ggtagtggg ttttggttaag tgaatttata aaacaaaaat acaagatgat 1260
ctattaatct cacaaatatt atagaaaagc ttaaaattaca gggtcagtta aaaccctgtg 1320
gccatcactc acacagaaca ccccaggaaa tcataaacct atacattagt gcattctaaga 1380
ctttaagcaa ttacacatct gttttactat acattgtttt acatcttaaa aacagtaaaa 1440
tccatcaaat aacttcttac tgaatgcata gatttagaat gagtagttac acatttttct 1500
acaactatct atataactgc agaaattgtt ttttcttgta aacttgtttt cttatttaga 1560
aatcaaaaga tgttcccata ttaccagaag gtttccctca cagtaaaagag agataatgtc 1620
tatacctcag atgcaaaaat caataagggc aatttgaagt ttctaagtgt tctatactct 1686
tgacag

<210> 42
<211> 1340
<212> DNA
<213> H. sapiens

<220>
<221> exon
<222> (668)... (816)

<400> 42
atagtttttg gaactagggc cttttattag aacatatgag acaattaagg tggagtacaa 60
tttttatttc ataattttct aaaaatttct agctataatg tacaaatata tttacttaaa 120
aatattatta agatcttagc ttgaatctaa aagagtagtt ggtacaagga tttcagccat 180
actctcaaca tagtccacag ttcacttgaa ccaaagataa aagaattagc ttaattgatt 240
gtgtaaaacta gactattttct tagaaaatta tttttatggg tagagtagaa ttaattgatt 300
atggagctca aagagttgtt taaatgtccg tatgctacta ttgaagcttt aagagaaaag 360
aaattttatg ttttaactttc tatggctcat ttttaataat gtttatgatt atgagcatac 420
tgatgcgaca ttagagatgt agcttaacct cacaatttct ctactacttt gtctttctta 480
taaatacaca tgggcaaaat atgtaataca taaaattaaa ttatatctat atatgaatat 540
gtgtatatat ttttcaaaag acagatatatt gctacatttt ttgcctacat tattctaaac 600
cctttcagaa atttacctaa agtaattatc ttgtgtcctc cacctttttt tttcttattc 660
ctgtcaggaa gacccactac attatctgag acaatgggga aagctgacgt atggcttatt 720
cgaaaactct ggaattttca gtttccatat ccaactctac caaatgttga tttgtttgga 780
ggactccact gcaaacctgc caaacccctg cctaaggtaa acatactttt gttgttttta 840
ttttgttggc tttgaatttt cagtagaaat gattctatag tcttctttca gagtgtttga 900
cttacactga aagaagatg ggaatgggtt ggggtaaaag agataccaat tagaaactca 960
tgtgcacgtt aataccatca cacgtatatg agttttatga gtattacaaa tagagaggaa 1020
tactaaggag actttgaaaa taggggttgg taaattaaag tcttcattat gcaataccta 1080
agaaggtatt ggtcatccaa tcaataataa tttacaaaag gattagcaca aaacacaggt 1140
aagtcagaaa ttttcagaga aaaaaataga cacagtttct gtccccacat accttacatt 1200
ctacttcaaa agatagaata tgtgcaagta ataaaaatta tataaaaaact attatctgaa 1260
ggaaaaacgc aataccaaga aagcatcagt ggagataata gaaagtatcc tgcagtcact 1320
gattagtaag atgggtaccc

<210> 43
<211> 1822
<212> DNA
<213> H. sapiens

<220>
<221> exon
<222> (732)... (863)

<400> 43
tatatacaat gtctgtatga taaatgagac tcttggcact aattcataga aattccaaat 60
tacattacca gactccagaa tgtcagcggg tcttaaccac cagcttttat ttattttatt 120
ttttttagtt ttgaaaaaac taccagaaaa ctctgaacaa actttaagtg aagtataaag 180
cattgttagag aaacataaat gtagatataa aattatccca actgtgagta gcttatcttc 240
agagctcata gttaggggaag taaaccacta actgtttcca actaagagaa ttctacagaa 300
aacctgcctg aaataaacac aagggattta gtagaacaac aatataggat taaagctgag 360
tgggtccact ttccaagaac ctatattagt aacttttagt atgaaagtga agagtcgtgt 420
attaatattt ttaacattat ctccctgaca acaatgtaat agctccattt cttttctccc 480
ttacacacat gcacacaaat acatacacat acacacatat ttacacaaat atccttaaca 540
gcatccacct atctcatatt atacatctac ttgcaaaaaa actgagtgat tgggtcagtt 600
aaaaaatatt atttactcca ataattcttc aaaaactctg attttctctc ttttagtaatt 660
tgcaaccaat cttttgtag tgcctgctgt gctaatactc ttttgtgatg aagcaaatc 720
tttcttcaca ggaaatggaa gactttgtac agagctctgg agaaaatggg gttgtgtgtg 780
tttctctggg gtcaatggtc agtaacatga cagaagaaag ggccaacgta attgcatcag 840
ccctggccca gatcccaaaa aaggttaagt gaagtgcctt actggtgtgg aaaactactg 900
aaagaggctg ttaaagtttg aagtaatcca attatagaaa cttctgataa atgtgaagtt 960
gaccaaaaag tgaaaaatta gaacaaggat aatcttgag aaactatgag aagtttgaaa 1020
attgtggttg cattttttt taaatggtgt taagtatgaa cattccccta tgtaaaatat 1080
ctgacaataa attgaatgga gaaaggtatt taaaaggtgt ttggagactt ctcacctcct 1140
gtccataaaa ttttgaattg tgtatgtgat ctacatagga aaggatatta aagagtagat 1200
tgaactcttc catagctgaa tatagcctta aatatgcttg tatagcatcc accgacagaa 1260
gtaatagttg tgcctcagac ttagggtgtg catgtggccc tggaggaggt actacccttg 1320
gtatgcataa gtatgtccta ttagcatcag tgggaactca gtactccata tgtattcaca 1380

WO 00/06776

PCT/US99/16675

aaaggcaact	tgagaccac	agttattttt	aatttctgat	attaacactc	atacatactg	1440
ctgaatttaa	ctcaatatat	ttcagttaag	tgaaaatggt	gcttaatgta	gtcttttagaa	1500
tgactttcag	gtgtttttcac	aaaaaacgta	tatccagaac	tgtgtccttt	tagaaataca	1560
agtataaattt	ttgataatta	gottcaaaac	agttttccta	atctcagcag	tatccaatga	1620
gtgaagaaca	cttgactgac	tcttgggtca	cctctattac	ttattgtact	ctggaagctc	1680
ttgtgtgaatg	tttacgatta	tgggatgtag	tatttctggt	tgcactttaa	gtcaaatgct	1740
tgtataaaat	acgtgacaac	aaatggagaa	tattggctct	gttagtagtt	atgcggtata	1800
tctctgtttt	aaggatcttt	gg				1822

<210> 44
 <211> 1591
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (138)... (225)

<221> exon
 <222> (1067)... (1286)

attctattta	cattagcctt	tgagtagttc	ttatttacta	acatcccttg	atctcattcc	60
tactctttat	acagttctca	cattctataa	cttttgaatt	ccactcatgg	aataaaatat	120
tttctttatt	gtaacaggtt	ctgtggagat	ttgatgggaa	taaaccagat	accttaggtc	180
tcaatactcg	gctctacaag	tggatacccc	agaatgacct	tctaggtaag	actctgggtga	240
acaaactactg	aatatattag	taacagcaca	ttagagtgtt	aatagtccat	catgaaacaa	300
gctttattgaa	tatttggtaa	ggaaaaacaa	aatgtaacct	ctttatattg	attttccagt	360
cttaaggggag	aaagaatata	ttataatttt	tggcatttta	tgatatacac	ccacattctt	420
tatagtctga	atcgggggaa	tctttatttc	aggtgttatt	atatctcaca	aaatttttca	480
ataacttctt	gggtctgtct	tctgtctctt	atttctacaa	ctttacacct	gtttttttcc	540
tctcccgag	gggttattga	aatgccacta	aaaataatag	ctcttctatc	accagtgaat	600
ctgtattttc	tgaagaatta	aactgctaata	cttaatacata	cagtgtatgat	acattttcacg	660
atgaagtgtg	acctgtcctt	cctcaatcct	agcaccacca	ccaaaccact	gactgtctgcc	720
ttgccacccc	catatatcac	actctgtgac	tgtcacttaa	aataagagtt	cacttcatgc	780
ctatctcttt	gctgtctctt	tttttgacaa	tttttgaaat	ctagaatgca	atttttcatt	840
agcccaactg	gaaatcttgt	attgttttgc	agtctgaagt	cacacacacc	glatagcctt	900
cagttacata	cccagtacaa	gtacgtgttt	tttctctcga	agtctgaaac	acaatttttaa	960
tttagttcag	tgttttagct	ggaaaaacact	gtcactttca	gagcctttca	ttgtgcatct	1020
cattttattc	ctatagtagta	ttttgctaaa	attcatccaa	tcttaggtca	tccaaagacc	1080
agagctttta	taactcatgg	tggagccaat	ggcatctacg	aggcaatota	ccatggggtc	1140
cctatgtgtg	ggattccatt	gtttgccgat	caacctgata	acattgctca	catgaaggcc	1200
agggggagcag	ctgttagagt	ggacttcaac	acaatgtoga	gtacagactt	gctgaatgca	1260
ttgaagagag	taattaatga	tccttctgtg	gtagaacaat	atttttccact	aggtgggtatt	1320
tacagatagc	ttctcttgtc	aatagttagt	gtgagtttca	tccttttttat	aagagactaa	1380
ttttgaaaga	atttaatatg	tttaaccaatc	tgaatctgac	ttttattttt	ataagttatt	1440
taaaaattga	atttgaacaa	catatcatcta	aagaatagcc	agtttagtgaa	acaattttct	1500
acacaaaaat	aatttttaaa	ggatatagat	aatacaaaaa	atacattttc	taaaaatttg	1560
acataattaa	tccatagaag	aaaggaagaa	t			1591

<210> 45
 <211> 596
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (19)... (549)

ctttattttt	atctttcaga	tataaagaga	atgttatgaa	attatcaaga	attcaacatg	60
atcaaccagt	gaagcccctg	gatcgagcag	tcttctggat	tgaatttgtc	atgcgccaca	120

```

aaggagctaa acaccttcgg gttgcagccc acgacctcac ctggttccag taccactctt 180
tggatgtgat tgggttcctg ctggtctgtg tggcaactgt gatatttatc gtcacaaaat 240
gttgtctgtt ttgtttctgg aagtttgcta gaaaagcaaa gaagggaata atgattagt 300
tatactcgag atttgaagct ggaaaacctg atagggtgaga ctacttcagt ttattccagc 360
aagaaagatt gtgatgcaag atttctttct tcctgagaca aaaaaaaaaa aagaaaaaaa 420
aatcttttca aaatttactt tgtcaaataa aaatttgttt ttcagagatt taccacccag 480
ttcatgggta gaaatatttt gtggcaatga agaaaacact acggaaaata aaaaataaga 540
taaagcotta tgagctcgta ttgaaatttg ttgaacttat atcgcggtac ctactg 596

```

```

<210> 46
<211> 20
<212> DNA
<213> H. sapiens

```

```

<400> 46
cttggctaatt ttatctttgg 20

```

```

<210> 47
<211> 19
<212> DNA
<213> H. sapiens

```

```

<400> 47
cccactaccc tgactttat 19

```

```

<210> 48
<211> 20
<212> DNA
<213> H. sapiens

```

```

<400> 48
ggacataacc atgagaaatg 20

```

```

<210> 49
<211> 19
<212> DNA
<213> H. sapiens

```

```

<400> 49
agctctgctt caaagacac 19

```

```

<210> 50
<211> 21
<212> DNA
<213> H. sapiens

```

```

<400> 50
tgtccgtatg ctactattga a 21

```

```

<210> 51
<211> 21
<212> DNA
<213> H. sapiens

```

```

<400> 51
tgtgctaata cctttgtaaa t 21

```

```

<210> 52
<211> 22
<212> DNA
<213> H. sapiens

```

WO 00/06776

PCT/US99/16675

<400> 52	
tttttttttc tattcctgtc ag	22
<210> 53	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 53	
ctttacccca cccattt	17
<210> 54	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 54	
ccottgatct cattcctact	20
<210> 55	
<211> 24	
<212> DNA	
<213> H. sapiens	
<400> 55	
aactggctat tctttagatg tatg	24
<210> 56	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 56	
cattcctact ctttatacag ttctc	25
<210> 57	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 57	
cccccgattc agactat	17
<210> 58	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 58	
ccottgatct cattcctact	20
<210> 59	
<211> 24	
<212> DNA	
<213> H. sapiens	
<400> 59	
aactggctat tctttagatg tatg	24
<210> 60	
<211> 18	
<212> DNA	

WO 00/06776

PCT/US99/16675

<213> H. sapiens	
<400> 60	
tcctccgaag tctgaaac	18
<210> 61	
<211> 23	
<212> DNA	
<213> H. sapiens	
<400> 61	
tataaaaagg atgaaactca cac	23
<210> 62	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 62	
caagcccca agttatgt	18
<210> 63	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 63	
cagtaggatac cgcgatataa	20
<210> 64	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 64	
tctgaggggt tttgtctgta	20
<210> 65	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 65	
ccgcgatata agttcaacaa	20
<210> 66	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 66	
ggacataacc atgagaaatg	20
<210> 67	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 67	
ttaagagcgg atgagttgt	19
<210> 68	

WO 00/06776

PCT/US99/16675

<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 68	
tcacatcatgca acagattaag	20
<210> 69	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 69	
cactacaggg aaaaatagca	20
<210> 70	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 70	
accctttgtg tacagtctca	20
<210> 71	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 71	
agctctgctt caaagacac	19
<210> 72	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 72	
ttgcctacat tattctaacc c	21
<210> 73	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 73	
ctttacocca cccattt	17
<210> 74	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 74	
cattcctact ctttatacag ttctc	25
<210> 75	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 75	
cccccgattc agactat	17

<210> 76
<211> 25
<212> DNA
<213> H. sapiens

<400> 76
cattcctact ctttatacag ttctc 25

<210> 77
<211> 17
<212> DNA
<213> H. sapiens

<400> 77
cccccgattc agactat 17

<210> 78
<211> 18
<212> DNA
<213> H. sapiens

<400> 78
tcctccgaag tctgaaac 18

<210> 79
<211> 23
<212> DNA
<213> H. sapiens

<400> 79
tataaaaagg atgaaactca cac 23

<210> 80
<211> 20
<212> DNA
<213> H. sapiens

<400> 80
tctgaggggt ttgtctgta 20

<210> 81
<211> 22
<212> DNA
<213> H. sapiens

<400> 81
ttttttgtct caggaagaaa ga 22

<210> 82
<211> 24
<212> DNA
<213> H. sapiens

<400> 82
aaaaaaagaa aaaaaaatct tttc 24

<210> 83
<211> 20
<212> DNA
<213> H. sapiens

WO 00/06776

PCT/US99/16675

<400> 83 ccgcgatata agttcaacaa	20
<210> 84 <211> 22 <212> DNA <213> H. sapiens	
<400> 84 tgcattgcac caggatgtct gt	22
<210> 85 <211> 21 <212> DNA <213> H. sapiens	
<400> 85 gcattgcacc aagatgtctg t	21
<210> 86 <211> 23 <212> DNA <213> H. sapiens	
<400> 86 tcctggatga gcttattcag aga	23
<210> 87 <211> 23 <212> DNA <213> H. sapiens	
<400> 87 tcctggatga gcctattcag aga	23
<210> 88 <211> 21 <212> DNA <213> H. sapiens	
<400> 88 cattttgggtt atatttttca c	21
<210> 89 <211> 21 <212> DNA <213> H. sapiens	
<400> 89 cattttgggtt ttatttttca c	21
<210> 90 <211> 21 <212> DNA <213> H. sapiens	
<400> 90 cataactaga aagttctgta a	21
<210> 91 <211> 21 <212> DNA	

WO 00/06776

PCT/US99/16675

<213> H. sapiens	
<400> 91	
cataactagg aagttctgta a	21
<210> 92	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 92	
cctggctaca cttttgaaaa	20
<210> 93	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 93	
cctggctaca tttttgaaaa	20
<210> 94	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 94	
gaagaccac tacattatct g	21
<210> 95	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 95	
gaagaccac tacgttatct g	21
<210> 96	
<211> 26	
<212> DNA	
<213> H. sapiens	
<400> 96	
aattttcagt ttccatatcc actctt	26
<210> 97	
<211> 26	
<212> DNA	
<213> H. sapiens	
<400> 97	
aattttcagt ttctcatcc actctt	26
<210> 98	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 98	
taggtctcaa tactcggctc ta	22
<210> 99	

WO 00/06776

PCT/US99/16675

<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 99	
taggtctcaa tactcggctg ta	22
<210> 100	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 100	
tacaagtgga taccaccaga	19
<210> 101	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 101	
tataagtgga taccaccaga	19
<210> 102	
<211> 26	
<212> DNA	
<213> H. sapiens	
<400> 102	
gggagaaaga atacattata attttt	26
<210> 103	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 103	
gggagaaaga atacttataa ttttt	25
<210> 104	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 104	
ttccattggt tgccgatcaa c	21
<210> 105	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 105	
ttccattggt tgctgatcaa c	21
<210> 106	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 106	
gaatgcattg aagagagtaa t	21

<210> 107
 <211> 21
 <212> DNA
 <213> H. sapiens

 <400> 107
 gaatgcattg cagagagtaa t 21

 <210> 108
 <211> 22
 <212> DNA
 <213> H. sapiens

 <400> 108
 ctggctctgtg tggcaactgt ga 22

 <210> 109
 <211> 22
 <212> DNA
 <213> H. sapiens

 <400> 109
 ctggctctgtg tggcgactgt ga 22

 <210> 110
 <211> 19
 <212> DNA
 <213> H. sapiens

 <400> 110
 taagataaag ccttatgag 19

 <210> 111
 <211> 19
 <212> DNA
 <213> H. sapiens

 <400> 111
 taagataaag acttatgag 19

 <210> 112
 <211> 1976
 <212> DNA
 <213> H. sapiens

 <220>
 <221> CDS
 <222> (11)...(1598)

 <400> 112
 taagaccagg atg tct ctg aaa tgg acg tca gtc ttt ctg ctg ata cag 49
 Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln
 1 5 10

 ctc agt tgt tac ttt agc tct gga agc tgt gga aag gtg cta gtg tgg 97
 Leu Ser Cys Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp
 15 20 25

 ccc aca gaa tac agc cat tgg ata aat atg aag aca atc ctg gaa gag 145
 Pro Thr Glu Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu
 30 35 40 45

ctt gtt cag agg ggt cat gag gtg act gtg ttg aca tct tcg gct tct Leu Val Gln Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser 50 55 60	193
act ctt gtc aat gcc agt aaa tca tct gct att aaa tta gaa gtt tat Thr Leu Val Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr 65 70 75	241
cct aca tct tta act aaa aat gat ttg gaa gat tct ctt ctg aaa att Pro Thr Ser Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile 80 85 90	289
ctc gat aga tgg ata tat ggt gtt tca aaa aat aca ttt tgg tca tat Leu Asp Arg Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr 95 100 105	337
ttt tca caa tta caa gaa ttg tgt tgg gaa tat tat gac tac agt aac Phe Ser Gln Leu Gln Glu Leu Cys Trp Glu Tyr Tyr Asp Tyr Ser Asn 110 115 120 125	385
aag ctc tgt aaa gat gca gtt ttg aat aag aaa ctt atg atg aaa cta Lys Leu Cys Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu 130 135 140	433
caa gag tca aag ttt gat gtc att ctg gca gat gcc ctt aat ccc tgt Gln Glu Ser Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys 145 150 155	481
ggt gag cta ctg gct gaa cta ttt aac ata ccc ttt ctg tac agt ctt Gly Glu Leu Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu 160 165 170	529
cga ttc tct gtt ggc tac aca ttt gag aag aat ggt gga gga ttt ctg Arg Phe Ser Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Gly Phe Leu 175 180 185	577
ttc cct cct tcc tat gta cct gtt gtt atg tca gaa tta agt gat caa Phe Pro Pro Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln 190 195 200 205	625
atg att ttc atg gag agg ata aaa aat atg ata cat atg ctt tat ttt Met Ile Phe Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe 210 215 220	673
gac ttt tgg ttt caa att tat gat ctg aag aag tgg gac cag ttt tat Asp Phe Trp Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr 225 230 235	721
agt gaa gtt cta gga aga ccc act aca tta ttt gag aca atg ggg aaa Ser Glu Val Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys 240 245 250	769
gct gaa atg tgg ctc att cga acc tat tgg gat ttt gaa ttt cct cgc Ala Glu Met Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg 255 260 265	817
cca ttc tta cca aat gtt gat ttt gtt gga gga ctt cac tgt aaa cca Pro Phe Leu Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro 270 275 280 285	865
gcc aaa ccc ctg cct aag gaa atg gaa gag ttt gtg cag agc tct gga	913

WO 00/06776

PCT/US99/16675

Ala Lys Pro Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly	
290 295 300	
gaa aat ggt att gtg gtg ttt tct ctg ggg tcg atg atc agt aac atg	961
Glu Asn Gly Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met	
305 310 315	
tca gaa gaa agt gcc aac atg att gca tca gcc ctt gcc cag atc cca	1009
Ser Glu Glu Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro	
320 325 330	
caa aag gtt cta tgg aga ttt gat ggc aag aag cca aat act tta ggt	1057
Gln Lys Val Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly	
335 340 345	
tcc aat act cga ctg tac aag tgg tta ccc cag aat gac ctt ctt ggt	1105
Ser Asn Thr Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly	
350 355 360 365	
cat ccc aaa acc aaa gct ttt ata act cat ggt gga acc aat ggc atc	1153
His Pro Lys Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile	
370 375 380	
tat gag gcg atc tac cat ggg atc cct atg gtg ggc att ccc ttg ttt	1201
Tyr Glu Ala Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe	
385 390 395	
gcg gat caa cat gat aac att gct cac atg aaa gcc aag gga gca gcc	1249
Ala Asp Gln His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala	
400 405 410	
ctc agt gtg gac atc agg acc atg tca agt aga gat ttg ctc aat gca	1297
Leu Ser Val Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala	
415 420 425	
ttg aag tca gtc att aat gac cct gtc tat aaa gag aat gtc atg aaa	1345
Leu Lys Ser Val Ile Asn Asp Pro Val Tyr Lys Glu Asn Val Met Lys	
430 435 440 445	
tta tca aga att cat cat gac caa cca atg aag ccc ctg gat cga gca	1393
Leu Ser Arg Ile His His Asp Gln Pro Met Lys Pro Leu Asp Arg Ala	
450 455 460	
gtc ttc tgg att gag ttt gtc atg cgc cac aaa gga gcc aag cac ctt	1441
Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu	
465 470 475	
cga gtc gca gct cac aac ctc acc tgg atc cag tac cac tct ttg gat	1489
Arg Val Ala Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp	
480 485 490	
gtg ata gca ttc ctg ctg gcc tgc gtg gca act gtg ata ttt atc atc	1537
Val Ile Ala Phe Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile	
495 500 505	
aca aaa ttt tgc ctg ttt tgt ttc cga aag ctt gcc aaa aca gga aag	1585
Thr Lys Phe Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys	
510 515 520 525	
aag aag aaa aga g attagttata tcaaaagcct gaagtggat gactgaaaga	1638
Lys Lys Lys Arg	

```

tgggactcct cctttatttc agcatggagg gttttaaatg gaggatttcc ttttccctgt 1698
gacaaaacat cttttcacta cttaccttgt taagacaaaa tttattttcc agggatttaa 1758
tacgtacttt agtttgaatt attctatgtc aatgattttt aagctatgaa aaatacaatg 1818
gggggaagga tagcatttgg agatatacct aatgttaaat gacgagttac tggatgcagc 1878
acgccaaacat ggcacatgta tacatatgta gctaacctca cgttgtgcac atgtacccta 1938
aaacttaag tataatttaa aaaaagcaaa gggtagccg 1976

```

<210> 113
 <211> 530
 <212> PRT
 <213> H. sapiens

<400> 113

```

Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln Leu Ser Cys
1      5      10      15
Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu
20     25     30
Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu Leu Val Gln
35     40     45
Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser Thr Leu Val
50     55     60
Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr Pro Thr Ser
65     70     75     80
Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile Leu Asp Arg
85     90     95
Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr Phe Ser Gln
100    105    110
Leu Gln Glu Leu Cys Trp Glu Tyr Tyr Asp Tyr Ser Asn Lys Leu Cys
115    120    125
Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu Gln Glu Ser
130    135    140
Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys Gly Glu Leu
145    150    155    160
Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu Arg Phe Ser
165    170    175
Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Phe Leu Phe Pro Pro
180    185    190
Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Ile Phe
195    200    205
Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe Asp Phe Trp
210    215    220
Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val
225    230    235    240
Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys Ala Glu Met
245    250    255
Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg Pro Phe Leu
260    265    270
Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro
275    280    285
Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly
290    295    300
Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met Ser Glu Glu
305    310    315    320
Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val
325    330    335
Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly Ser Asn Thr
340    345    350
Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly His Pro Lys
355    360    365
Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile Tyr Glu Ala
370    375    380

```

Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln
 385 390 395 400
 His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Leu Ser Val
 405 410 415
 Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala Leu Lys Ser
 420 425 430
 Val Ile Asn Asp Pro Val Tyr Lys Glu Asn Val Met Lys Leu Ser Arg
 435 440 445
 Ile His His Asp Gln Pro Met Lys Pro Leu Asp Arg Ala Val Phe Trp
 450 455 460
 Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala
 465 470 475 480
 Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp Val Ile Ala
 485 490 495
 Phe Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Phe
 500 505 510
 Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys Lys Lys
 515 520 525
 Arg Asp
 530

<210> 114
 <211> 2312
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (692)...(1425)

<400> 114

accctcctgc	tcccatctgc	catgatcaact	ggaaaaccct	catttatctt	ttaaagggtc	60
cagaaaatgc	taatctatag	agatagaaat	tagattagt	gttgccctagg	gtaggatgga	120
tgcaaaatct	cagagtgggg	ggtagaggc	tattgtatag	aatcttttgg	agataatact	180
gattattgta	gtgaaagtta	aattctgtga	atatactagg	aaacattgaa	ctgtacacac	240
taattggtga	gtcatatggt	atatgaatta	tgtgtcaaca	aagttttaga	agacattact	300
tgcaaccaga	tattaaaaaa	tgccgtttga	gttggtataat	tacttcttct	ctctatgtca	360
agggcaccga	acaggcagga	gcctctcaact	tgccactgtt	cttaacagta	ttataaaaata	420
attacataag	acagggttact	tacatattct	aggctataaa	aattattgct	tgactagagt	480
aattgtaaac	ataaaagaac	accaaaacaca	ctaaaataaa	tatgaggtca	tcaatctttt	540
gttggtctoc	ttggcatgca	cctattcaga	ctgttagtat	tatgtattta	cttcaaattt	600
tagcagttat	attttaactt	gattgatttt	tcctcagata	taagtatgag	aatgacaga	660
aagaaacaac	aactggaaaa	gaagcattgc	ataagaccag	gatgtctctg	aaatggacgt	720
cagtccttct	gctgatacac	ctcagttgtt	actttagctc	tggaagctgt	ggaaagggtc	780
tagtgyggcc	cacagaatac	agccattgga	taaatatgaa	gacaatcctg	gaagagcttg	840
ttcagagggg	tcatgaggtg	actgtgttga	catcttcggc	ttctactctt	gtcaatgcca	900
gtaaatcatc	tgctattaaa	ttagaagttt	atcctacatc	tttaactaaa	aatgatttgg	960
aagattctct	tctgaaaatt	ctcgatagat	ggatatatgg	tggttcaaaa	aatacatttt	1020
ggtcatattt	ttcacatta	caagaattgt	gttggaata	ttatgactac	agtaacaagc	1080
tctgtaaaaga	tgcagttttg	aataagaaac	ttatgatgaa	actacaagag	tcaaagtttg	1140
atgtcattct	ggcagatgcc	cttaatccct	gtggtgagct	actggctgaa	ctatttaaca	1200
taccctttct	gtacagtctt	cgattctctg	ttggctacac	atttgagaag	aatggtggag	1260
gatttctgtt	ccctccttcc	tatgtacctg	ttgttatgtc	agaattaagt	gatcaaatga	1320
ttttcatgga	gaggataaaa	aatatgatac	atatgcttta	ttttgacttt	tggtttcaaa	1380
tttatgatct	gaagaagtgg	gaccagtttt	atagtgaagt	tctaggtaag	tcattgtgtc	1440
aactgggtct	tattaagtct	taacttttct	gtgcctttga	aggtgagctt	atataaatat	1500
aatgtcagaa	gatagtgttt	ttaagggaac	ttatgaattg	caaatgtaag	atgatctatc	1560
agtcctcaaaa	atattataga	atgttgacct	tatagaatca	gttagaacc	tggggccatc	1620
actactacag	gacaccocaga	gagtcataaa	ccttcattgt	aaagcactaa	tgatttcttt	1680
aaactatcac	atatcatttt	gctatacatt	ttttcatctt	taaaaaagt	caatagatac	1740
ctcaagaaac	atcttcatga	aggcagacac	ataaatcttg	tatttacaca	tatttctaga	1800
aaaattatca	atgcaggatt	gaggaatttg	tttctotttg	agttcctcag	tttctcatt	1860

WO 00/06776

PCT/US99/16675

tagaaattaa	atattgtttt	tcatgtaaga	aggattcctt	cacagttgag	taatatagtg	1920
gctctactcc	agaaacagaa	gcctaaaaact	tgagatttct	aatgtttata	cattccttca	1980
ataacagggt	gacaattatt	tctttcaaaa	actgaaatct	tggtgaaagt	gaacatctaa	2040
gttttaatct	atattttatt	aaactgcac	tctccatcaa	agaaaaatag	ggccaaatta	2100
agggagagca	catatctcta	tgcaataaaa	ttctgaaaat	gttttaatto	tcatttgtaa	2160
atatatttat	tttaaaaatc	taattatatt	aagatcttac	gatgaaccaa	gacagtagta	2220
ggtgtaaga	tttcagtggt	gagctcaaaa	aactcatggt	ttactttgag	aaccaaggat	2280
caagggtcag	cttaataaac	tgtagacact	ag			2312

<210> 115
 <211> 1021
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (413)...(565)

accatgatcc	aatcacctgc	cactgggtcc	ctccctggac	acatggggat	tatggggatt	60
ataaattcaag	atgagaggag	atattgggtgg	ggacagtcac	accatattag	tgactttatt	120
taataattat	ttatgattgt	gaatatactg	atgttacatt	aaagatgtga	tttcttctta	180
cagatctctg	aatacattgc	cttccttata	tatacatatg	agcaacatat	gcaataaaaa	240
aaatctaaat	tatgactata	tataaatgta	tttatatata	ttttatcaat	gcacagacat	300
tttatataatg	tttgggtatg	ttattccaag	tcctttcagg	aaaatacctg	catattcaaa	360
taacaattct	cggtgttagct	accttttggt	ttgttttggt	ttttccatc	aggaagaccc	420
actacattat	ttgagacaat	ggggaaaagt	gaaatgtggc	tcattcgaac	ctattgggat	480
tttgaatttc	ctcgccatt	cttaccacaa	gttgattttg	ttggaggact	tcactgtaaa	540
ccagcccaac	ccctgcctaa	ggtaaatgta	ttctgttttc	atgtgtttgc	ttgacatttt	600
cagaaggaat	ggctggatat	gtttctttca	gagtgtttaa	ctcagagtga	ggggaatatg	660
ggaggtcaca	aaacaggact	tgccattaga	aatcatata	ttctgtagt	atcacaagta	720
tgtaaatgtt	attatcatta	aagaccacaa	aggtttacta	gggagatttt	gaaaacaggg	780
ttggttaaa	taaggcccttc	attgtgccac	ccaaaagata	gtatgattca	tttcttcaaa	840
aaatatttgt	agagtgtata	atacaaacca	caggtaagtg	ctggattttc	agagaataaa	900
ggtagcacag	tttctgctcc	ctcatgcctt	acattgtact	ttgaaagata	gaataaaaac	960
aagtgaaaaa	gaaaagtcta	aaaagtgtta	ttaaggaaag	accacaatga	taaagaaata	1020
t						1021

<210> 116
 <211> 480
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (43)...(174)

tgctgttgct	ctttcttgat	agaacaaatt	ctttcttcac	aggaaatgga	agagtttggt	60
cagagctctg	gagaaaaatg	tattgtggtg	ttttctctgg	ggtcgatgat	cagtaaacatg	120
tcagaagaaa	gtgccacat	gattgcatca	gcccttgccc	agatcccaca	aaaggttaga	180
taaaagtgcct	taactgtgga	tggtactaa	atgaatctgt	taaaactctc	aagagtccat	240
tacagaatag	ttctgcctga	aaatttaact	gctatgatag	ttctaattat	ctcagacatc	300
tgttcaaacg	aaaaacatat	atggaagatc	ttaaaatcat	aaagagagga	gttttggttg	360
ataataacgt	tggtattaat	attgtgatca	gaaggaaata	tatttaagag	gtgctagtga	420
agtttggtat	tatcatggta	tcgtagcatg	tacatagaaa	tcactaaatt	ctgccctgtc	480

<210> 117
 <211> 1602
 <212> DNA
 <213> H. sapiens

<220>
<221> exon
<222> (368)...(455)

<221> exon
<222> (1295)...(1514)

<400> 117
tgagtcaagg gctgactttg aatagaatgg gaggtagggt tgccctaagc agcttaactt 60
ttcccttttag catagagttt ggggttgccaa gatttatattt cctttcacaa tctcatgtgt 120
ctagctatta tggtagaat gtcattatctt ctttatatac aaaattgatt ataaaagtaa 180
cgacattaaa cgtgggtatt caacttacct caaactttta gtagtctca ttacttgaca 240
tcacttcttc ttatttcttc atcttttata tggattaaact aactgattat taactctctc 300
agaattctaa catgctatgt ttttagagtt ctattcattg aacaagatat tttccttgcc 360
ctaacaggtt ctatggagat ttgatggcaa gaagccaaat actttagggt ccaatactcg 420
actgtacaag tggttacccc agaattgacct tcttggttaag attctggaga acaaacagt 480
aatatattag taacagcaaa ttggagtgat aatagttcaa cataaaacaa acatatttag 540
cattttattt tggaaaacta aaaaacaaat caaatttaac tactttatat ttattttcca 600
gtcttagtat aaaaagaatg cactatagta gttggcattt tattacatac agtcacattc 660
tttatggta gaataaaaat ctctttgttc aggtgtaatt tctcttcaca ggttttaaat 720
aacatcctgg attttctgtc tgtctcctat ttatgcagct ttacctctgt tctttccctc 780
actgcagggg tatttcaaca ggcactgaaa aatagcggac acttttctat taccagtgc 840
tctacttttt atgggaataa ataaccaatc tttatcatga taaaatgata acacatttca 900
tgatgatgca taaccggtcc ttctcagccc ccactccac cctactccct gctgcctttt 960
aaaaaaaatt aaatatttta aatattttta gtatttaaat attttttaaa tatgtaaatg 1020
tgacctcatt atttataata cttaaaagac caggttcttg tataccaat cttattcttt 1080
ttttttgcac atttttaatt ttttaattaa aatagctttt ttcattttgt tcacctggca 1140
attcttctga aatttgaaaa caatttcaat gcagttttgt gggataatg ttacctaggg 1200
aacagttttg ctttaagttc cttatattgt gcatttctta ttcaattctc ataccttgta 1260
attaataatt ttgttaaaat gcattccact ttaggtcacc ccaaaaccaa agcttttata 1320
actcatgggt gaaccaatgg catctatgag gcgactcacc atggggtccc tatgggtggg 1380
attcccttgt ttgcgatca acatgataac attgctcaca tgaagccaa gggagcagcc 1440
ctcagtggtg acatcaggac catgtcaagt agagatttgc tcaattgcatt gaagtcatg 1500
attaatgacc ctgtgtgagt attacagttt tgtgaccagg tggattttat aaattatttt 1560
gtcaacagtg aatatgaatt ttaaccggtt ttaagagac ta 1602

<210> 118
<211> 978
<212> DNA
<213> H. sapiens

<220>
<221> exon
<222> (326)...(978)

<400> 118
caaaaagatc attctcaaat tccatttcca ctatcttact tatagcactt agaattggctc 60
ataatatatt ctgctccaga aaacattaac tttcccaccg aaaattccat ttttcatttt 120
taaagggtatt tgcagtgat aaactccaa tttaaaaacc aaactttctg taatgacatg 180
aattaaaaca ttgaaatttc atgccaattc agtgacactt actttcaatc atttgtgtga 240
cacttttcaa agaccatcca tagacttgat atgcttaagc aataaattta cttttaatgt 300
tgatatcttt atatttatcc ttcagctata aagagaatgt catgaaatta tcaagaattc 360
atcatgacca accaatgaag ccctggatc gagcagctct ctggattgag tttgtcatgc 420
gccacaaagg agccaagcac ctctgagtc cagctcaca cctcacctgg atccagtacc 480
actcttttga tgtgatagca ttctgctgg cctgcgtggc aactgtgata tttatcatca 540
caaaattttg cctgttttgt ttccgaaagc ttgcaaaac aggaagaag aagaaaagag 600
attagttata tcaaaagcct gaagtggat gactgaaaga tgggactcct cttttatttc 660
agcatggagg gttttaaatg gaggtttcc ttttctctgt gacaaaacat cttttcacta 720
cttaccttgt taagacaaaa ttattttcc agggatttaa tacgtacttt agttggaatt 780
attctatgtc aatgattttt aagctatgaa aaatacaatg gggggaagga tagcatttgg 840
agatatacct aatgttaaat gacgagttac tggatgcagc acgccaacat ggcacatgta 900
tacatatgta gctaacctca cgttgtgcac atgtacccta aaacttaag tataatttaa 960

WO 00/06776

PCT/US99/16675

aaaaagcaaa gggtagcg

978

<210> 119
<211> 20
<212> DNA
<213> H. sapiens

<400> 119
catgcaccta ttcagactgt

20

<210> 120
<211> 20
<212> DNA
<213> H. sapiens

<400> 120
tgggtgtcct gtagtagtga

20

<210> 121
<211> 25
<212> DNA
<213> H. sapiens

<400> 121
attgattttt cctcagatat aagta

25

<210> 122
<211> 22
<212> DNA
<213> H. sapiens

<400> 122
tcataatttc ccttaaaaac ac

22

<210> 123
<211> 22
<212> DNA
<213> H. sapiens

<400> 123
atatgttttg gtaggttatt cc

22

<210> 124
<211> 18
<212> DNA
<213> H. sapiens

<400> 124
ccatattccc ctcaactct

18

<210> 125
<211> 23
<212> DNA
<213> H. sapiens

<400> 125
atacctgcat attcaaataa caa

23

<210> 126
<211> 18
<212> DNA
<213> H. sapiens

WO 00/06776

PCT/US99/16675

<400> 126	
tatccagcca ttccttct	18
<210> 127	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 127	
agttttgtgg gtataatgtt ac	22
<210> 128	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 128	
aaacgggtta aaattcata	19
<210> 129	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 129	
tcataccttg taattaataa ttttg	25
<210> 130	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 130	
cgggttaaaa ttcatttca	20
<210> 131	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 131	
tcatgccaat tcagtgc	18
<210> 132	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 132	
accctccatg ctgaaat	17
<210> 133	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 133	
tcaaagacca tccatagact t	21
<210> 134	
<211> 19	

WO 00/06776

PCT/US99/16675

<212> DNA	
<213> H. sapiens	
<400> 134	
ggagtcccat ctttcagtc	19
<210> 135	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 135	
attgattttt cctcagatat aagta	25
<210> 136	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 136	
atttactggc attgacaag	19
<210> 137	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 137	
attgattttt cctcagatat aagta	25
<210> 138	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 138	
tgtacagaaa gggatgtta aa	22
<210> 139	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 139	
aaaaatkatt tggaagattc	20
<210> 140	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 140	
tcataatttc ccttaaaaac ac	22
<210> 141	
<211> 23	
<212> DNA	
<213> H. sapiens	
<400> 141	
atacctgcat attcaaataa caa	23

WO 00/06776

PCT/US99/16675

<210> 142	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 142	
tatccagcca ttccttct	18
<210> 143	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 143	
tcataccttg taattaataa ttttg	25
<210> 144	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 144	
cgggttaaaa ttcatttca	20
<210> 145	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 145	
tcaaagacca tccatagact t	21
<210> 146	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 146	
ggagtcccat ctttcagtc	19
<210> 147	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 147	
tgatacagct cagttgttac	20
<210> 148	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 148	
tgatacagct cggttgttac	20
<210> 149	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 149	

WO 00/06776

PCT/US99/16675

tgttgacatc ttcggttct	20
<div><210> 150</div> <div><211> 20</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 150</div> tgttgacatc gtcggcttct	20
<div><210> 151</div> <div><211> 23</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 151</div> ctttaactaa aaatgatttg gaa	23
<div><210> 152</div> <div><211> 23</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 152</div> ctttaactaa aaattatttg gaa	23
<div><210> 153</div> <div><211> 22</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 153</div> tttaacatac cctttctgta ca	22
<div><210> 154</div> <div><211> 22</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 154</div> tttaacatac cctttccgta ca	22
<div><210> 155</div> <div><211> 22</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 155</div> ttggaggact tcactgtaaa cc	22
<div><210> 156</div> <div><211> 22</div> <div><212> DNA</div> <div><213> H. sapiens</div>	
<div><400> 156</div> ttggaggact tcagtgtaaa cc	22
<div><210> 157</div> <div><211> 23</div> <div><212> DNA</div> <div><213> H. sapiens</div>	

WO 00/06776

PCT/US99/16675

<400> 157	
tatgaggcga tctaccatgg gat	23
<210> 158	
<211> 23	
<212> DNA	
<213> H. sapiens	
<400> 158	
tatgaggcaa tctaccatgg gat	23
<210> 159	
<211> 24	
<212> DNA	
<213> H. sapiens	
<400> 159	
cccttggttg cggatcaaca tgat	24
<210> 160	
<211> 24	
<212> DNA	
<213> H. sapiens	
<400> 160	
cccttggttg tggatcaaca tgat	24
<210> 161	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 161	
aaagagaatg tcatgaaatt at	22
<210> 162	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 162	
aaagagaata tcatgaaatt at	22
<210> 163	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 163	
gcttgccaaa acaggaaaga a	21
<210> 164	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 164	
gcttgccaaa aaaggaaaga a	21

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/16675

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C120

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages
------------	--

Relevant to claim No.

X LEVESQUE E. ET AL.,: "Isolation and
characterization of UGT2B15 : a
UDP-Glucuronosyltransferase encoded by a
polymorphic gene"
PHARMACOGENETICS,
vol. 7, no. 4, - August 1997 (1997-08)
pages 317-325, XP000852552
cited in the application
see whole doc. esp. results p.320 ff.

1-10

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

8 November 1999

22/11/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer _____

Müller, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/16675

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RITTER J.K. ET AL.,: "Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells" J. BIOL. CHEMISTRY, vol. 265, no. 14, - 15 May 1990 (1990-05-15) pages 7900-7906, XP002121919 the whole document</p>	1-3
X	<p>JIN. C.J. ET AL.,: "cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily" BIOCHEM. BIOPHYS. RESEARCH COMMUNICATIONS, vol. 194, no. 1, - 15 July 1993 (1993-07-15) pages 496-503, XP002121839 cited in the application the whole document</p>	1-3
X	<p>WO 92 12987 A (US) 6 August 1992 (1992-08-06) see whole doc. esp. claims and summary</p>	1-10
A	<p>RITTER J.K. ET AL.,: "Cloning of two human liver bilirubin UDP-glucuronosyl-transferase cDNAs with expression in COS-1 cells" J. BIOL. CHEMISTRY, vol. 266, no. 2, - 15 January 1991 (1991-01-15) pages 1043-1047, XP002121838 the whole document</p>	1-3
A	<p>GREEN M D ET AL: "STABLE EXPRESSION OF A HUMAN LIVER UDP-GLUCURONOSYLTRANSFERASE (UGT2B15) WITH ACTIVITY TOWARD STEROID AND XENOBIOTIC SUBSTRATES" DRUG METABOLISM AND DISPOSITION, vol. 22, no. 5, 1 September 1994 (1994-09-01), pages 799-805, XP002039718 ISSN: 0090-9556 cited in the application</p>	
A	<p>CIOTTI ET AL: "GENETIC POLYMORPHISM IN THE HUMAN UGT1A6 (PLANAR PHENOL) UDP-GLUCURONOSYLTRANSFERASE: PHARMACOLOGICAL IMPLICATIONS" PHARMACOGENETICS, vol. 7, no. 7, 1997, pages 485-495 495, XP002113205 ISSN: 0960-314X the whole document</p>	

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/16675

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	DE WILDT S.N. ET AL.,: "Glucuronidation in humans" CLIN. PHARMACOKINETICS, vol. 36, no. 6, - June 1999 (1999-06) pages 439-452, XP002121840 the whole document	
P,X	LEVESQUE E. ET AL.,: "Characterization and substrate specificity of UGT2B4: a UDP-glucuronosyltransferase encoded by a polymorphic gene" PHARMACOGENETICS, vol. 9, no. 2, - April 1999 (1999-04) pages 207-216, XP000852554 the whole document	1-10
P,X	MACLEOD S.L. ET AL.,: "a genetic polymorphism in UGT2B15 as a risk factor for breast and prostate cancer" PROC. AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, - March 1999 (1999-03) pages 243-244, XP002121841 the whole document	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 99/16675

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9212987 A	06-08-1992	AU 1227892 A	27-08-1992